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Abstract 
Characterization of the Nucleocytoplasmic Transport of the Cutaneous 
HPV8 E7 Protein  
 
Zeynep Onder 
Thesis Advisor: Prof. Junona Moroianu, Ph.D 
 
Some non melanoma skin cancers (NMSC) have been associated with human 
papillomavirus (HPV) pathogenesis, like epidermodysplasia verruciformis (EV) 
and squamous cell carcinoma (SCC) (3, 31, 34, 35, 102).  EV is a genetically 
inherited skin disease that develops when the individuals are infected with 
cutaneous HPV types belonging to the β-genus, especially types 5 and 8 (3, 11, 
30, 65). Transgenic mouse lineages expressing all early genes of cutaneous 
HPV8 develop papillomas, dysplasias and SCC after UV irradiation and this 
correlates with enhanced HPV8 oncogenes expression (3, 28, 80, 102).  
  
We have previously discovered that the nuclear localization of mucosal HPV16 
E7 and HPV11 E7 proteins is mediated by their zinc-binding domain via a Ran-
dependent pathway and independent of nuclear import receptors and that a 
patch of hydrophobic residues within the zinc-binding domain of HPV16 E7 and 
HPV11 E7 proteins is responsible for their nuclear import via hydrophobic 
interactions with FG nucleoporins (5, 26, 43, 57, 75). Here we investigated the 
nucleocytoplasmic traffic of cutaneous HPV8 E7 protein using confocal 
microscopy to analyze the intracellular localization of EGFP-8E7, its subdomains 
and its mutants after transient transfections. We also investigated the nuclear 
import ability of GST-8E7, its subdomains and mutants using in vitro nuclear 
import assays in digitonin-permeabilized HeLa cells. In addition, we performed 
isolation assays to study the direct interaction between HPV8 E7 and two FG 
nucleoporins, Nup62 and Nup153 or the nuclear export receptor, CRM1.   
 
We found that the nuclear import of cutaneous HPV8 E7 is mediated by a nuclear 
localization signal (NLS) located within its zinc-binding domain. Furthermore, we 
determined that the hydrophobic residues within the 65LRLFV69 patch are 
responsible for the nuclear import and nuclear localization of HPV8 E7 via direct 
hydrophobic interactions with FG nucleoporins, Nup62 and Nup153, whereas the 
positively charged arginine 66 plays no significant role in the function of the NLS. 
In addition, we examined the nuclear export mechanism of cutaneous HPV8 E7 
protein and showed that it has a leucine-rich nuclear export signal (NES) in its C-
terminal domain that is recognized by the CRM1 nuclear export receptor. These 
studies are essential for understanding the nucleocytoplasmic traffic of cutaneous 
HPV8 E7 protein.  	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Human Papillomaviruses 
 
Papillomaviruses are the most common sexually transmitted infection worldwide, 
with the majority of individuals who engage in sexual activity becoming infected 
at some point in their lifetime (100). In the United States over 6 million new cases 
of HPV infection are estimated every year and approximately 20 million people 
are infected with an HPV at any given point (89). HPV is responsible for more 
than 550,000 new cases of human cancer annually with 25,000 of them occurring 
in the United States (17, 89). 
High risk mucosal human papillomaviruses (HPV) are now well accepted to be 
the predominant cause of anogenital cancers (17, 48, 59, 62, 65, 102). 
Precancerous cervical lesions are detected by routine cytological screening with 
the Papanicolaou (Pap) test followed by close monitoring of cytology, HPV 
testing and if results persist, also by colposcopy and biopsy (48). All together the 
diagnosis, management and follow-up of patients with cervical lesions create a 
burden on the health care systems worldwide (48). Current HPV vaccines 
represent a promising preventive approach towards HPV infection but they do not 
provide any protection to previously infected people and do not have effects on 
virus induced cellular lesions (89). In the future significant number of HPV related 
cancers are expected to keep occurring due to massive anti-HPV vaccination 
campaigns and cultural and socio-economic reasons preventing vaccination (89). 
High risk HPVs are also responsible for up to 65% vaginal cancers, 50% of vulvar 
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cancers, and 35% of penile cancers (17). Furthermore, over the years, it has 
become apparent that the effect of HPV is more far-reaching than originally 
thought, with a strong link between infection and the development of 90% of anal 
cancers and 45 to 90% of oropharyngeal cancers (100). There is ongoing 
investigation into its role in the development of esophageal, lung, head and neck, 
anus cancers and squamous basal cell carcinomas.  
Human papillomaviruses are small, non-enveloped, double stranded DNA tumor 
viruses (55 nm in diameter), that show tropism for squamous basal epithelial 
cells (3, 17, 21, 48, 58, 59, 62, 65). First identified and described in cottontail 
rabbits, papillomaviridae family is now thought to occur in many species of 
mammals and birds (21, 58). Over 200 different HPV types belonging to 
papillomaviridae family have been isolated and phylogenetically classified into 
the alpha, beta, gamma, mu and nu genera  (sharing <60% nucleotide identity), 
species (60-70%) and types (71-89%) (21, 48, 58, 65). The majority of them can 
be grouped in either the alpha genus or beta genus based on sequence 
similarities in L1 open reading frame (ORF) (21, 28, 48, 58, 62, 65). The beta-
HPVs are associated with cutaneous lesions in humans, whereas the alpha-
HPVs, often called mucosal, are seen primarily in mucosal infections and 
cutaneous lesions in humans and primates (21). Mucosal HPVs, approximately 
40 types known to infect the cervical epithelium, can further be classified as 
either low risk or high risk (21, 48, 58, 62, 65). Low risk HPVs, such as HPV 6 
and 11, are often associated with genital warts (condylomata acuminata) (21, 28, 
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48, 58, 62, 65). It is estimated that such lesions affect about 1% of all sexually 
active adults in the United States (89).  Infections with low risk HPVs are rarely 
found to lead to cancers even if left untreated (48, 58). On the other hand high 
risk HPVs, such as HPV 16 and 18, are detected in invasive cervical carcinomas 
(48, 58, 59, 62, 65). HPV16 is the most prevalent high risk HPV in the general 
population, and is responsible for approximately 50% of all cervical cancers (23). 
Overall, more than 99% of cervical carcinomas and 25-30% of oropharyngeal 
cancers, as well as, 30-50% penile, 60-90% vagina, and 50% vulvar cancers are 
associated with high risk mucosal HPV infections (17, 48, 58, 62, 65).    
 
The approximately 8 kb HPV genome encoding eight or nine ORFs can be 
divided into 3 major portions: ~ 1 kb long control region (LCR) containing the 
elements necessary for replication and transcription; ~ 4 kb early (E) region that 
encodes three oncogenes, E5, E6 and E7, and two regulatory proteins, E1 and 
E2; and ~ 3 kb late (L) region that encodes the L1 and L2 capsid proteins (21, 48, 
59, 62, 65). HPVs infect cells in the basal layer of stratified squamous epithelia 
that become exposed as a result of small microwounds (48, 59, 62, 65, 81). The 
receptor involved in the internalization of the virus is currently unknown. 
However, it is now widely accepted that a heparan sulfate proteogylcan 
dependent conformational change in the capsid and furin cleavage of L2 are 
involved in slow viral internalization (48, 79, 81). Although different mechanisms 
of endocytosis, involving either clathrin, caveolin, or tetraspanin domains have 
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been proposed for different HPV types; a consensus about the pathway involving 
tetraspanin domains for internalization and intracellular trafficking of the HPV 
capsid has been emerged (79, 81, 86). Following infection, the viral genomes are 
retained in the nucleus at a low copy number as episomes that replicate along 
with host DNA (48, 62, 65).  
 
The life cycle of HPV is closely linked to the differentiation status of the host cell 
and is controlled through tightly regulated activation of the early and late viral 
promoters as the infected basal cell differentiates (48, 65). In the basal 
epithelium, where the initial stages of the viral life cycle take place, the viral early 
genes are expressed by the activation of the viral early promoter (48). E1 protein 
is a DNA-binding protein that has helicase and ATPase activity (58, 81). The E1 
protein acts in viral DNA replication by recruiting cellular factors to the origin of 
replication (58, 81). The E2 protein is a site-specific DNA binding protein that 
plays a role in the viral DNA replication by recruiting the viral DNA helicase, E1 
protein, as well as episome maintenance during mitosis, and transcriptional 
regulation by keeping E6 and E7 oncoprotein expressions repressed (48, 58, 62, 
65, 81). The roles of E4 and E5 proteins have not been fully elucidated; however, 
it has been shown that E4 may facilitate the release of viral particles by 
destabilizing the keratin network and facilitating the shedding of virion from 
differentiated epithelia and, regulate gene expression (62, 65, 81). The E5 protein 
is a hydrophobic transmembrane protein localized to the plasma membrane, 
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Golgi apparatus, and ER membrane (62, 65). It shows weak transformation 
activity via acting on receptor tyrosine kinase signaling pathways and inducing 
anchorage-independent growth (48, 62, 65).  
 
High risk E6 and E7 proteins together are necessary and sufficient for the 
efficient immortalization of primary squamous epithelial cells (48, 58, 59, 62, 65, 
66, 103). The E6 oncoproteins from high risk mucosal HPVs are characterized by 
the presence of PDZ-binding motif through which they interact with a number of 
cellular PDZ domain containing substrates and cooperate in their degradation 
(50). The oncogenicity of high risk E6 protein is mostly due to its ability to recruit 
cellular E3 ubiquitin ligase E6-associated protein (E6AP) for the degradation of 
tumor suppressor protein p53, thereby disrupting the p53-mediated cellular 
reaction to DNA damage and trophic sentinel response (50, 58, 62, 65, 102, 
103). E6 has also been shown to interact with p53 transcription factors, p300 and 
ADA3 in addition with c-myc to activate the expression of catalytic telomerase 
subunit hTERT (48, 58, 62, 65). The biochemical and biological properties of E7 
protein will be discussed in the following section. Recently, 88 cellular factors 
have been identified as HPV targets for their expression in HPV-induced cervical 
lesions from dysplasia to cancer showing HPV proteins’ ability to reprogram host 
cell (55).  
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As an HPV infected cell differentiates, activation of the late promoter causes the 
expression of late genes and high-level amplification of the viral genome (48, 65).  
Finally, in highly differentiated suprabasal cells, viral DNA is packaged into newly 
formed capsids and progeny virions are released from the cell in a nonlytic way 
(48, 65). 55 nm icosahedral capsid is formed by 360 copies of major capsid 
protein, L1, organized into 72 capsomeres and up to 72 copies of minor capsid 
protein, L2, most likely positioned in the center of each L1 capsomer (48, 65, 79). 
Events leading to viral malignancies represent a failed outcome for the virus and 
exist outside the normal viral life cycle. During the malignant progression of the 
high risk HPV positive lesions, the viral DNA often integrates into the host 
genome near common fragile sites, resulting in the disruption of E2 gene and 
thereby resulting in continuous expression of E6 and E7 oncoproteins (48, 58, 
59, 62).  
 
Human Papillomavirus E7 Oncoprotein 
 
The HPV E7 proteins are small acidic phosphoproteins of approximately 100 
amino acids that are structurally and functionally related to Adenovirus E1A 
protein and large T antigen from Simian Vacuolating Virus 40 (SV40) (25, 48, 59, 
65, 103).  The E7 proteins can be structurally divided into 3 domains: the 
conserved region (CR) 1, 2, and carboxyl terminal (C-terminal) domain (Fig. A). 
In contrast to well structured carboxyl terminal, CR1 and CR2 form the fully 
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disordered amino terminus of the protein that interacts with a high variety of 
target proteins (15, 65, 103). A portion of CR1 and the entire CR2 domains have 
sequence homology with that of adenoviral E1A (48, 59, 65, 103). CR1 domain is 
necessary for cellular transformation and RB degradation in high risk HPVs and 
the CR2 domain contains a conserved pRB family binding site (LxCxE domain) 
and a consensus casein kinase II (CKII) phosphorylation site (48, 52, 59, 65, 74, 
103). The C-terminal domain contains a zinc-binding domain that is composed of 
two Cys-X-X-Cys motifs, separated by approximately 30 amino acids mediating 
the dimerization of E7 protein and its association with multiple cellular complexes 
(8, 18, 48, 56, 59, 78, 91, 103).   
 
 
 
FIG.A. Schematic representation of HPV16 E7 oncoprotein. The unstructured 
amino terminal of HPV16 E7 is required for cellular transformation, pRB binding 
(LXCXE) and degradation. It also has a casein kinase II phosphorylation site. The 
carboxyl terminal domain of HPV16 E7 represents a zinc-binding fold, which is 
arranged as two Cys-X-XCys motifs separated by 29 amino acid residues (59). 
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The E7 protein, lacking enzymatic and DNA binding activities, is constitutively 
expressed in tumor cells, and plays a role both in the induction and maintenance 
of the transformed phenotype due to its ability to associate with and abrogate the 
normal functioning of cellular targets (58, 59, 62, 65, 102, 103). Several studies 
done on mucosal HPV E7s have reported that E7 can bind to over 20 cellular 
proteins to override the G1/S cell cycle check point control, modulate the 
expression of cellular genes and deregulate the cellular carbohydrate metabolism 
(59, 62, 65, 78, 103).  
 
The best-characterized targets of HPV E7 protein are retinoblastoma tumor 
suppressor protein (pRB) and pocket proteins. The binding of E7 to pRB and 
pocket proteins, p107 and 130, disrupts the interaction between pRB and cellular 
E2F transcription factors, and inhibits pRB-mediated repression of E2F 
responsive genes, allowing S-phase entry and cell cycle progression (48, 58, 59, 
62, 65, 78). In addition to binding to pRB, high risk HPV E7 protein also mediates 
proteasomal degradation of RB (13, 48, 58, 59, 65, 78, 82). To keep the host cell 
in a replication competent state, high risk HPV E7 proteins also associate with 
cyclin dependent kinase inhibitors (CKI) p21CIP1 and p27KIP1, abrogating their 
function, and bind to cdk2/cyclin A and cyclin E complexes, increasing cdk2 
activity (48, 58, 59, 62, 65, 78). The HPV E7 proteins also interact with histone 
deacetylases (HDACs) that function as transcriptional corepressors at E2F-
inducible promoters, transcriptional coactivators p300, CBP and pCAF, and 
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transcription factors, c-fos and c-jun (48, 58, 59, 62, 65, 78). Recently, HPV16 E7 
expressing cells have shown to have increased polyploidy due to high levels of 
DNA replication initiation factor, Cdt1, causing rereplication of host DNA without 
entering mitosis (27, 59, 65, 78). To deregulate host cell carbohydrate 
metabolism, HPV E7 proteins shift the M2 pyruvate kinase equilibrium and 
increase the glycogen affinity of glycogen-degrading enzyme acid α-glucosidase 
via direct binding (58, 59, 103, 104, 105). HPV E7 interaction with cytoplasmic 
microtubule associated N-end rule ubiquitin ligase p600 has also been 
determined to prevent anoikis (38, 58, 59, 62, 78). Recently, yeast two-hybrid 
analysis identified the protein gelsolin as an HPV16 E7 oncoprotein binding 
partner leading to the changes of cell cycle, to inhibition of apoptosis and to the 
increase of cell survival (61). 
 
Cutaneous Human Papillomaviruses  
 
Non melanoma skin cancers (NMSCs) including basal cell carcinomas and 
squamous cell carcinomas represent the most prevalent cancers in Caucasian 
populations worldwide (3, 22, 28, 73). Over one million cases are reported yearly 
in the United States and more than 60,000 cases in the United Kingdom (3, 24). 
Although 99% of NMSC cases are curable, treatment costs exceed $500 million 
in the United States every year (73). Since exposure to UV radiation, along with 
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fair skin and immune status, represent the greatest risk factors, it is not surprising 
that NMSC emerges primarily on the sun-exposed skin of the host (3, 28, 73).  
 
A linkage between HPV and the development of cutaneous squamous cell 
carcinomas was first demonstrated in patients with the rare autosomal recessive 
disorder epidermodysplasia verruciformis (EV) (3, 31, 34, 35, 102). EV is 
characterized by flat wart like lesions in early childhood, which develop into SCC 
in 30-50% of the patients after one or two decades of persistence (3, 24, 28, 58, 
65, 73, 102). Among the 14 types of HPVs found in benign tumors of EV patients, 
HPV 5 and 8 are specifically linked to malignant lesions and actinic keratoses 
(AK) and have been classified as high risk types (3, 11, 24, 30, 34, 58, 65, 73, 
99, 102). In addition to EV patients, EV-HPVs have also been identified in 
NMSCs of 30-50% of immunocompetent and up to 90% of immunocompromised 
individuals, as well as in healthy skin, as indicated by several epidemiological 
studies (3, 12, 14, 24, 28, 35, 51, 65, 73).  
 
Although studied for two decades, further effort is still needed to understand the 
role of EV-HPV in NMSC since the molecular mechanisms altered by mucosal 
and cutaneous HPVs seem to differ from each other (102). EV-HPV colonization 
of human skin occurs early in life with a great variety of different HPV types, 
which are found in NMSC lesions, as well as in normal skin (6, 28, 73, 102). Thus 
EV-HPVs are part of normal microbiological flora of the cutaneous skin and viral 
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infection per se does not represent the major event in skin carcinogenesis (95). 
In contrast to anogenital cancers, which contain at least one copy of mucosal 
HPV DNA per tumor cell, not all the NMSC tumor cells show the presence of EV-
HPV DNA by in situ hybridization (3, 35, 73, 102). The genome organizations of 
HPV 5 and 8 while comparable with that of other HPVs, lack the E5 ORF (30, 
97). EV-HPV E2, E6 and E7 proteins have been associated with cellular 
transformation in vitro and in vivo in contrast to E5, E6 and E7 proteins of 
mucosal HPVs (3, 28, 62, 72, 80, 102, 103). In contrast to high risk mucosal HPV 
E7 and E6 proteins, the E7 protein of high risk HPV8 has been shown to bind to 
pRB with only 34% of HPV16 E7 affinity, and the cutaneous HPV E6 proteins fail 
to bind to p53 and promote its proteolytic degradation (3, 73, 82). 
 
Compared to mucosal HPVs, relatively little is known about cellular pathways 
affected by EV-HPVs. To date, there has been no cell culture line derived from 
EV patients (73, 102). However, transgenic mice expressing the early genes of 
HPV8 under the control of human keratin-14 promoter spontaneously develop 
benign tumors and, in some cases (6%), SCC, demonstrating the role of EV-
HPVs in the development of skin cancer (3, 28, 80, 102). Tumor development 
can be further induced by UV irradiation or by mechanical irritation within three 
weeks after treatment (3, 28, 80, 102).  HPV8 E7 protein has been found to 
increase the expression of matrix metalloproteinases leading to the disruption of 
the basement membrane and keratinocyte invasion through the underlying 
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dermis in organotypic cultures and the HPV8 transgenic mice (2, 3, 4, 28). In 
addition, the HPV8 E7 has been shown to increase the terminal differentiation 
and hyperproliferation of human keratinocytes (2, 3, 4, 28). The E7 proteins of 
both HPV 8 and 5 induce transformation in rodent cells only in the presence of an 
activated H-ras gene, whereas the HPV8 E6 protein was shown to cause 
transformed phenotype, anchorage independent growth and reduced serum 
requirement (3, 28, 40, 73, 97).  In contrast to mucosal HPVs, HPV8 E6 and E7 
proteins failed to show true immortalizing abilities in primary human 
keratinocytes, where HPV8 E7 showed only a weak induction in proliferation (3, 
28, 82). It has been shown that HPV5 E6 protein targets proapoptotic protein Bak 
for proteolytic degradation, thereby effectively decreasing UVB-induced 
apoptosis in vitro and in regenerated epithelium, and overcoming the G1 cell 
cycle check point after UVB treatment (3, 28, 32, 41, 102). In addition, early 
tumor formation of HPV8-CER mice expressing all early genes of HPV 8 under 
the control of the human keratin-14 promoter has been associated with an 
upregulation of the oncogenic miRNA-17-5p, -21 and -106a and a 
downregulation of the tumor suppressive miRNA -155 and -206 (36). 
Furthermore, transgenic mice expressing viral oncoproteins E6 and E7 from 
different cutaneous EV-HPVs have found to show an increased susceptibility to 
UV induced and/or chemically induced skin carcinogenesis compared to wild type 
animals (92). Recently, HPV8 E7 expressing cells have been found to express 
high levels of epithelial cancer stem cell markers, CD44/EpCAM suggesting that 
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EV-HPVs may enable the persistence and accumulation of DNA damage during 
early carcinogenesis (37). Therefore, many studies focus on the link between UV 
radiation, EV-HPVs and development of NMSC (58, 73). 
 
Nuclear Import and Export of Macromolecules  
 
In eukaryotic cells, selective and regulated nucleocytoplasmic transport occurs 
via the nuclear pore complex (NPC), a large macromolecular structure embedded 
in the double membrane of nuclear envelope (63, 85). The NPC has a mass of 
125MDa in vertebrates, and contains approximately 30 different proteins, 
nucleoporins (Nups), in multiple copies (63, 85, 94). These nucleoporins arrange 
to form a conserved 8-fold symmetry, with each section consisting of cytoplasmic 
filaments, the nuclear basket and the central core (63, 85, 94). Nucleoporins can 
be classified into 4 families: pore membrane proteins (Poms) anchoring the NPC 
in the nuclear envelope; nucleoporins containing WD repeats, or a seven-bladed 
propeller motif, playing role in mRNA transport; structural Nups forming the core 
NPC; and phenylalanine-glycine (FG) nucleoporins, which are characterized by 
FxFG, GLFG or FG repeats separated by hydrophilic spacers (85, 87, 94). It is 
these unfolded hydrophobic FG nucleoporins that create a permeability barrier 
and facilitate the passage of nuclear receptors through the NPC via low affinity 
hydrophobic interactions (39, 67, 84, 85, 87, 94). FG nucleoporins are thought to 
constitute about half of the NPC mass, and while most are distributed 
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symmetrically; some FG nucleoporins are restricted to the cytoplasmic, central or 
nuclear side of NPC (84). For instance, Nup62 and Nup153 are localized at the 
central channel of NPC and on the nuclear basket, respectively (7, 84).  
 
Ions and small proteins up to 40 kDa can passively diffuse through the NPC 
channel (9 nm in diameter), while macromolecules larger than 40kDa require a 
nuclear localization signal (NLS) for import, or nuclear export signal (NES) for 
export, in order to pass through the NPC (63, 85, 87). Basic, or classical NLS, 
first characterized in nucleoplasmin and SV40 T large antigen, consists of either 
3-5 basic amino acid clusters or 2 groups of positively charged amino acids 
separated by 10-12 amino acids (63, 85). Since the characterization of classical 
NLS, many additional NLSs have been characterized. For instance, M9 NLS, first 
characterized in hnRNP A1 consists of 38 amino acids rich in glycine (76, 83).  
Generally, facilitated nuclear transport starts in the cytoplasm via the interaction 
between NLS containing cargo and the import receptor (63, 94). The biggest 
class of import receptors belongs to karyopherin β/importin β (Kap β/Imp β) family 
(63, 85, 87, 94). These import receptors bind to NLS containing cargo directly or 
indirectly via an evolutionary conserved adapter protein, Kap α  (63, 85, 87, 94). 
The Kap β/cargo complex then translocates though the NPC via interactions 
between Kap β and FG nucleoporins (63, 85, 87, 94). Binding of RanGTP to the 
transport complex in the nucleus disrupts the interaction between the cargo and 
import receptor, releasing the cargo inside the nucleus (63, 85, 94). The 
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concentration gradient of the small GTPase Ran and structural asymmetry of 
NPC are important for the directionality of transport (63, 85, 94). Many Ran 
independent nuclear import pathways have also been identified, such as β-
catenin, importin-β1, CRM1, exportin-t, Human T Lymphotropic Virus Type 1 
(HTLV) Tax protein and more (44, 54, 85, 87, 90). 
 
Nuclear export of proteins is facilitated by nuclear export receptors. To date the 
best-characterized nuclear export receptor, chromosome region maintenance 1 
(CRM1) binds to hydrophobic leucine rich NES containing cargoes in a RanGTP 
dependent manner (29, 39, 63, 85, 94). The canonical NES is defined as a L-X2-
3-L-X2-3-L-X-L motif, where leucine residues can be isoleucine, valine, 
phenylalanine or methionine (39, 45). RanGTP/CRM1/NES cargo complex 
translocates through the NPC and cargo is released into the cytoplasm by GTP 
hydrolysis of RanGTP (39, 63, 85, 94).  
 
Nucleocytoplasmic Transport of HPV E7 proteins 
 
Immunofluorescence studies have shown that HPV16 E7 and HPV11 E7 
oncoproteins are predominantly nuclear when expressed transiently in HaCat, 
U2OS and HeLa cell lines (5, 33, 43, 59, 62, 75). Previous studies in the 
Moroianu lab showed that glutathione S-transferase (GST) tagged 16E7 (GST-
16E7) and 11E7 (GST-11E7) were transported into the nucleus of digitonin-
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permeabilized HeLa cells in the presence of exogenous factors suggesting that 
16E7 and 11E7 enter the nucleus via a facilitated translocation pathway (5, 75). 
In addition, nuclear import of GST-16E7ΔDLYC that is unable to bind pRb or the 
pRb-related proteins, p107 or p130, in in vitro nuclear import assays revealed 
that 16E7 nuclear import was independent of pRb binding (5). Nuclar import of 
GST-16E7 in the presence of anti-karyopherin antibodies, anti-Kapβ1 and anti-
Kapβ2, used to specifically block import mediated by these karyopherins and lack 
of direct interaction between 16E7 and Kapβ1 or Kapβ2 showed that 16E7 import 
is not mediated by Kapβ1 and Kapβ2 pathways (5). Furthermore, in vitro nuclear 
import assays showed that Ran-GDP was sufficient for 16E7 and 11E7 nuclear 
import (5, 75). In addition, lack of binding between 16E7 and Ran or its import 
receptor, p10/NTF2 and between 11E7 and RanGDP or RanG19V suggested 
that 16E7 and 11E7 were not imported into the nucleus by ‘piggy-backing’ along 
with Ran (5, 75). Overall these data suggest that 16E7 and 11E7 enter the 
nucleus via a non-classical, Ran dependent, and nuclear import receptor 
independent pathway (5).  
 
Further studies by the Moroianu lab used transient transfection experiments in 
HeLa cells to analyze intracellular localization of 16E7 and its subdomains, 
16E71-37 (16nE7) and 16E738-98 (16cE7) (43). Fluorescent microscopy analysis 
revealed that EGFP-16E7 as well as its mutant defective in binding pRb, 
16E7ΔDLYC, localized mostly to the nucleus. Further transfection experiments 
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showed that EGFP-16nE7 localized mostly in the nuclear whereas EGFP-16cE7 
was mostly cytoplasmic (43). To determine whether 16cE7 mostly cytoplasmic 
localization was due to the absence of a NLS or the presence of a weak NLS and 
stronger NES, Leptomycin B (LMB) and Ratjadone A (RJA), that are CRM1 
specific nuclear export inhibitors, were used following transient transfection 
assays (43). This analysis revealed that the predominantly cytoplasmic 
localization of 16cE7 has changed to mostly nuclear localization in the presence 
of the nuclear export inhibitors suggesting a functional NES (43). Further studies 
showed that 16 E7 contained a leucine rich nuclear export sequence, 
76IRTLEDLLM84 in its C-terminal domain. In addition in vitro nuclear import 
analysis showed that GST-16cE7 was imported into the nucleus of digitonin-
permeabilized HeLa cells showing the involvement of zinc binding domain in the 
nuclear localization of 16E7. Similar experiments have shown that 11E7 
contained a NLS and an active NES in its C-terminal domain (57, 75). Overall 
these data suggest that 16E7 and 11E7 proteins can shuttle between the 
cytoplasm and nucleus (43, 57, 75). To further analyze the C-terminal NLS 
(cNLS) of both 16E7 and 11E7 site-directed mutagenesis was used to mutate 
cysteines involved in zinc coordination (26, 75). In vitro nuclear import assay and 
in vivo transient transfection were performed to analyze mutant proteins’ nuclear 
import and nuclear localization, respectively. These analyses showed that the 
zinc-binding domain is essential for the nuclear localization of both 16E7 and 
11E7 (26, 75). 
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It has been previously determined that a phenyl-Sepharose column mimics the 
specificity of FG nucleoporins and binds to the members of the karyopherin 
superfamily (77). Also, carrier independent translocation of proteins into the 
nucleus can occur via direct interactions between the studied protein and FG 
nucleoporins  (54, 71, 90). Previous work in the Moroianu lab showed the 
interaction between 11E7 with phenyl-Sepharose column and competition assays 
revealed that 11E7 nuclear import was blocked in the presence of excess 
karyopherin receptors (75). Based on these data hydrophobic patches of 16E7 
and 11E7 (65LRLCV69 and 65VRLVV69, respectively) were further analyzed to 
study their possible role in the nuclear localization of E7s using in vitro nuclear 
import assay and in vivo transient transfection assays (26, 57). It is important to 
note that this hydrophobic patch located in the C-terminal domain is conserved 
among different E7 oncoproteins and consists of 4 non-polar amino acids and a 
positively charged arginine at position 66. Studies in the Moroianu lab suggest 
that the hydrophobic residues within the hydrophobic patch are responsible for 
the nuclear localization and nuclear import of both 16E7 and 11E7, whereas the 
positively charged arginine 66 plays no significant role in the function of the cNLS 
(26, 57). To investigate the direct interactions between both 16E7 and 11E7 and 
FG nucleoporins, and the role of the hydrophobic patch, isolation assays were 
performed (26, 57). These analyses showed that 16E7, 11E7 and their respective 
C-terminal domains and respective arginine mutants were able to bind to the FG 
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repeats of Nup62 whereas the hydrophobic patch mutants were unable to bind 
(26, 57). Overall, these data strongly suggest that 16E7 and 11E7 are imported 
to the nucleus via hydrophobic interactions between their zinc-binding domain 
and the FG repeats of Nup62 (26, 57).  
 
In this study to further understand the function of cutaneous HPV8 E7 protein in 
the viral life cycle and transformation of the host cell, we investigated its 
nucleocytoplasmic trafficking. By analyzing the nuclear localization and nuclear 
import of cysteine mutants via transient transfections and nuclear import assays, 
respectively, we characterized that cutaneous HPV8 E7 protein had a nuclear 
localization signal located in its zinc-binding domain and mutations of cysteine 
residues taking part in zinc coordination prevents the proper functioning of cNLS. 
In addition, we showed that hydrophobic residues 65LRLFV69 within the zinc-
binding domain of cutaneous HPV8 E7 protein but not conserved arginine 66 
mediate both the nuclear localization and nuclear import of HPV8 E7 protein. 
Moreover, we discovered that the hydrophobic residues, 65LRLFV69, are 
essential for hydrophobic interactions with two FG nucleoporins, Nup62 and 
Nup153. Excess Kapβ2 competing with HPV8 E7 nuclear import further 
demonstrated that the import mechanism of HPV8 E7 is similar to that of 
karyopherins. In addition, anti-Nup62 antibody that specifically recognizes FG 
repeats of Nup62 blocked the import of GST-8E7 as Nup62 is located at the 
central transport channel and interacts with HPV8 E7 before Nup153, which is 
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located at the nuclear basket of NPC (7, 84). Furthermore, we showed that 
mucosal HPV16 E7 and HPV11 E7 proteins also interact with Nup153 via 
hydrophobic residues within their zinc-binding domains. We also discovered that 
the cutaneous high risk HPV5 E7 protein contains a cNLS mediating its nuclear 
import. In addition, HPV5 E7, similar to HPV8 E7, HPV16 E7 and HPV11 E7, 
directly interacts with FG repeats of Nup62 and Nup153 via its zinc-binding 
domain indicating that the import mechanism is conserved among E7 proteins of 
different HPV types. We also investigated the nuclear export mechanism of 
cutaneous HPV8 E7 protein and found that it has a leucine rich NES located 
within its C-terminal domain and recognized by the nuclear export receptor, 
CRM1. These data suggest that cutaneous HPV8 E7 shuttles between nucleus 
and cytoplasm.  
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Chapter 2 
Materials and Methods 
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Cell Culture 
HeLa cells (American Type Culture Collection) that are HPV18 positive cervical 
carcinoma cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; 
Sigma) supplemented with 10% heat inactivated Fatal Bovine Serum (FBS) 
(Sigma) and 1% Penicillin/Streptomycin solution (Sigma) in 5% carbon dioxide at 
37oC. DMEM supplemented with and without antibiotics and serum is herein 
referred to as DMEM + and DMEM -, respectively.   
 
Generation of GFP Expression Plasmids 
Enhanced Green Fluorescence Protein (EGFP) expression plasmid, pEGFP-C1 
(Clontech) was used to construct EGFP-8E7, EGFP-8nE71-42, EGFP-8cE743-103, 
EGFP-5E7, EGFP-5nE71-42, and EGFP-5cE743-103. EGFP-8E7, EGFP-8cE7, 
EGFP-5E7, and EGFP-5cE7 were prepared as follows: pEGFP-C1 plasmid was 
double digested with EcoRI and BamHI for 1 hour at 37oC, run on a 1% agarose 
gel, extracted from gel using QIAquick Gel Extraction Kit (Qiagen) and stored at -
20oC until ligation. 8E7, 8cE7, 5E7 and 5cE7 were PCR amplified from 8E7 and 
5E7 in Gateway vectors (generous gifts from Dr. Karl Munger) using primers with 
flanking EcoR1 and BamH1 restriction enzyme cutting sites (Table A). The PCR 
reaction buffer included 10X Pfx Amplification Buffer, 10mM dNTP mixture, 
50mM MgSO4, corresponding 0.3 mM forward and reverse primers, 2 ng plasmid 
DNA, 1 unit Pfx DNA polymerase and DNase free distilled water to bring the 
reaction volume to 50 uL.  A PCR cycle of 15 seconds at 94oC for denaturation, 
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30 seconds at 54oC for annealing and 90 seconds at 68oC for elongation was 
repeated for 25 cycles. PCR products were analyzed by 1% agarose gel and 
extracted from gel as previously described. Purified PCR products were then 
double digested with EcoRI and BamHI for 1 hour at 37oC and column purified 
using QIAquick Gel Extraction Kit (Qiagen). The double digested vector and 
insert (either 8E7, 8cE7, 5E7 or 5cE7) were ethanol precipitated with a 1:3 
vector:insert molar ratio using 2.5M ammonium acetate, 20 ug glycogen and 2 
volumes of ice cold 95% ethanol was added and the mixture was incubated 
overnight at -20oC.  The vector:insert mixture were then span down at 13000 rpm 
for 30 minutes at 4oC, resuspended in 200 uL ice cold 70% ethanol, span down 
at 13000 rpm for 20 minutes at 4oC. The supernatant was aspirated and the DNA 
pellet was air-dried at room temperature. Ligation was performed by 
resuspending the pellet in ligation buffer and water and then incubating it with 1 
uL T4 DNA ligase (NEB) at 16oC overnight.  The resulting plasmids were 
transformed into XL1-Blue competent E. coli (Stratagene), plated on 
LB/Kanamycin agar plates and incubated overnight at 37oC. Plasmids were 
isolated from colonies following BioRad Plasmid MiniPrep Kit  (BioRad) protocol 
and sequenced for verification (Eurofins MWG). Stock bacterial cultures were 
prepared by mixing 900 uL overnight bacterial stock with 100 uL sterile glycerol 
and stored in -80oC. Construction of EGFP-8nE7 and EGFP-5nE7 will be 
discussed in the following section.  
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Table A: Cloning Primers for pEGFP-C1 
 
Construct Primers 
EGFP-8E7 F 5’ GCGCGAATTCGATGATTGGTAAAGAGGTCACTGTGC 3’ 
R 5’ GCGCGGATCCTAATGATCCGCCATGTTTGCAGTTACC 3’ 
EGFP-8cE7 F 5’ GCGCGAATTCGGACATCGAAAGAACTGTATTC 3’ 
R 5’ GCGCGGATCCTTATGATCCGCCATGTTTGCAGTTACC 3’ 
EGFP-5E7 F 5’ GCGCGAATTCGATGATTGGTAAAGAGGTCACCGTGC 3’ 
R 5’ GCGCGGATCCTTAGGATCCGTCATGTTTGCAGTTTCC 3’ 
EGFP-5cE7 F 5’ GCGCGAATTCGGACAACGAAAGGATCTTTTAC 3’ 
R 5’ GCGCGGATCCTTAGGATCCGTCATGTTTGCAGTTTCC 3’ 
 
 
Site-directed Mutagenesis 
Site-directed mutagenesis was performed to generate EGFP-8nE71-42 and EGFP-
5nE71-42 using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) with 
EGFP-8E7 or EGFP-5E7 as template, and the corresponding mutagenesis 
primer pairs containing a stop codon at amino acid 43 (Table B). The cysteine 
mutants EGFP-8E7CC60AA, EGFP-8E7C91A, EGFP-8E7C91/94A, EGFP-8E7CGC56AAA, 
and EGFP-8cE7CC60AA, EGFP-8cE7C91A, EGFP-8cE7C91/94A, EGFP-8cE7CGC56AAA 
were generated using the same QuikChange Site-Directed Mutagenesis Kit 
(Stratagene) with EGFP-8E7 or EGFP-8cE7 as template, and the corresponding 
mutagenesis primer pairs (Table B). EGFP-8E7LRLFV65AAAAA, EGFP-8E7R66A, 
EGFP-8cE7LRLFV65AAAAA, and EGFP-8cE7R66A mutants were generated using the 
same QuikChange Site-Directed Mutagenesis Kit (Stratagene) with EGFP-8E7 or 
EGFP-8cE7 as template, and the corresponding mutagenesis primer pairs (Table 
B). Nuclear export signal mutants EGFP-8E7C91A/F79A and EGFP-8E7C91A/LLF82AAA 
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were generated using the same QuikChange Site-Directed Mutagenesis Kit 
(Stratagene) with EGFP-8cE7C91A as template, and the corresponding 
mutagenesis primer pairs (Table B). 
 
Briefly, each 50 uL reaction mixture contained either 20 or 50 ng DNA, 125 ng 
forward and reverse primers (Table B), 1 uL dNTP, 1 uL Pfu Turbo DNA 
Polymerase and some sterile water to bring the reaction volume to 50 uL. A PCR 
cycle of 30 seconds at 95oC for denaturation, 30 seconds at 55oC for annealing 
and 5 minutes at 68oC for elongation was repeated for 18 cycles. PCR products 
were then digested with 1 uL Dpn1 (Stratagene) for 1 hour at 37oC to eliminate 
methylated wild-type template DNA. XL1 Blue competent cells (Agilent 
Technologies) were then transformed with PCR products and plated on 
LB/Kanamycin plates.  Plasmids were extracted using Quantum MidiPrep Kit 
(Biorad) and sequenced for verification (Eurofins MWG). Stock bacterial cultures 
were prepared by mixing 900 uL overnight bacterial stock with 100 uL sterile 
glycerol and stored in -80oC.  
  
The EGFP-16E7, EGFP-16E7LRLCV65AAAAA and EGFP-16E7R66A plasmids were 
previously generated (26). The EGFP-11E7, EGFP-11E7VRLVV65AAAAA and EGFP-
11E7R66A plasmids were previously generated (57).  
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Table B: Mutagenesis Primers 
 
Construct Primers 
8nE7 F 5’ CGAACAGGAAACGGAGGAGGAGTAAGACATCGAAAGAACTG 3’ 
R 5’ CAGTTCTTTCGGTCTTATACTCCTCCTCCGTTTCCTGTTCG 3’ 
 
5nE7 F 5' GAAACGGAGGAGGAGCCTTAGAACGAAAGGATCTTTTAC 3'       
R 5' GTAAAAGATCCTTTCGTTCTAAGGCTCCTCCTCCGTTTC 3' 
 
8E7CC60AA & 
8cE7CC60AA 
F 5' CGT GTG GCT GCA GCG CAG CAC AGG TCA AGC TAC G 3' 
R 5' CGT AGC TTG ACC TGT GCT GCG CTG CAG CCA CAC G 3' 
 
8E7C91A & 
8cE7C91A 
F 5' CTGTTCAGAGACCTACAGCTTCTGGCACCTGAGTGCCGC 3’      
R 5' GCGGCACTCAGGTGCCAGAAGCTGTAGGTCTCTGAACAG 3' 
 
8E7C91/94A & 
8cE7C91/94A 
F 5’ CTACAGCTTCTGGCACCTGAGGCACGCGGTAACTGC 3’ 
R 5’ GCAGTTACCGCGTGCCTCAGGTGCCAGAAGCTGTAG 3’ 
 
8E7CGC56AAA  & 
8cE7CGC56AAA 
F 5’ CAAAATTGTTGCACCGGCAGCAGCAAGCTGCTGTCAGGTC 3’ 
R 5’ GACCTGACAGCAGCTTGCTGCTGCCGGTGCAACAATTTTG 3’ 
 
8E7LRLFV65AAAAA & 
8cE7LRLFV65AAAAA 
F 5’ GCTGTCAGGTCAAGGCAGCAGCAGCCGCCAACGCAACTGATC 3’ 
R 5' GATCAGTTGCGTTGGCGGCTGCTGCTGCCTTGACCTGACAGC 3’ 
 
8E7R66A & 
8cE7R66A 
F 5' CTGTCAGGTCAAGCTAGCCCTTTTTGTCAACGCAAC 3' 
R 5' GTTGCGTTGACAAAAAGGGCTAGCTTGACCTGACAG 3' 
 
8cE7C91A/F79A F 5' GATTCGGGTATCAGGACCGCACAAGAATTGCTGTTCAG 3'       
R 5' CTGAACAGCAATTCTTGTGCGGTCCTGATACCCGAATC 3’ 
 
8cE7C91A/LLF82AAA F 5' CAGGACCTTTCAAGAAGCAGCAGCAAGAGACCTACAGCTTCTG 3' 
R 5’ CAGAAGCTGTAGGTCTCTTGCTGCTGCTTCTTGAAAGGTCCTG 3' 
 
 
 
Transient Transfections 
HeLa cells plated at 50-70% confluency on 12mm poly-L-lysine coated glass 
coverslips 24 hours before transfection transiently transfected with EGFP 
construct of interest using Fugene 6 Transfection Reagent (Roche Applied 
Science, IN). Transfection mixture was prepared by adding 0.8ng:3uL 
DNA:Fugene ratio into serum free DMEM -  and incubated for 20 minutes at room 
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temperature. Cells media were changed to DMEM - before adding transfection 
mixture. Cells were incubated for 6 hours at 37oC. After 6 hours, the media was 
changed for DMEM + and incubated for another 16 hours. Cells were then 
washed three times with cold 1X Phosphate Buffered Saline (PBS), incubated 
with 3.7% paraformaldehyde for 10 minutes and washed three more times with 
1XPBS on ice.  Following the washes, coverslips were mounted with Vectashield-
DAPI mounting medium to identify the nuclei of cells.  
 
Fixed cells were analyzed with a Leica TCS Sp5 broadband confocal microscope 
using a 63X immersion oil objective and 1.6X optical zoom and representative 
images were taken using Leica LAS AF software (Leica Microsystems). 
Intracellular localization of EGFP-tagged proteins was phenotyped as either 
mostly nuclear, pancellular, or mostly cytoplasmic and data from at least 4 
experiments were quantitated and graphical representations were used to display 
average values and standard deviations.  
 
Ratjadone A (RJA) Treatment 
To block nuclear export RJA (Calbiochem), which is a CRM-1 specific nuclear 
export inhibitor, was used. 20 hours post-transfection with EGFP fusion plasmids 
one set of HeLa cells were treated with 10 ng/mL RJA in DMEM + for 4 hours in 
dark. After treatment, cells were fixed and analyzed by confocal microscopy as 
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previously described. EGFP-16E7 tagged with nuclear export signal of HIV-rev 
(EGFP-16E7NesRev) was used as a positive control for RJA experiments.  
 
Immunoblot Analysis 
Immunoblot analysis was performed to analyze that EGFP fusion proteins were 
expressed at collect molecular weight and at similar amounts and that they are 
not degraded. HeLa cells transfected with EGFP fusion plasmids were lysed 
mechanically 24 hours post-transfection in 1% SDS-PAGE buffer on ice and 
lysates were denatured at 95oC for 5 minutes. Equal amounts of lysates (in 
volume) were then separated on a 12% polyacrylamide gel at 45 mA and 
transferred onto a nitrocellulose membrane in Tris-Glycine transfer buffer for 45 
minutes at 75 volts. Equal protein loading and transfer were checked by Ponceau 
staining. The blots were blocked in 5% non-fat milk blocking solution in 1XPBS 
with 0.1% Tween for 1 hour at room temperature, incubated in 1:5000 diluted 
anti-EGFP (Clontech) in blocking solution for 1 hour at room temperature and 
washed three times with blocking solution on a rocker. The blots were further 
incubated in 1:1500 diluted goat anti-mouse IgG conjugated with horseradish 
peroxidase (HRP) secondary antibody (Santa Cruz) in blocking solution for 30 
minutes at room temperature and washed three times with 1XPBS. HyGLO 
Chemiluminescent HRP Antibody Detection Reagent (Denville Scientific) was 
used to develop the blots and the blot were exposed to HyBlot CL 
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autoradiography film (Denville Scientific) and developed using XO-MAT 
developer (Kodak).  
 
Generation of pGEX-E7 Plasmids and Mutants 
pGEX-4T1 expression plasmid was used to construct GST-8E7, GST-8nE71-42, 
GST-8cE743-103, GST-5E7, GST-5nE71-42 and GST-5cE743-103. GST-8E7, GST-
8cE7, GST-5E7 and GST-5cE7 were prepared as follows: pGEX-4T1 plasmid 
was double digested with EcoRI and XhoI for 1 hour at 37oC, run on a 1% 
agarose gel, extracted from gel using QIAquick Gel Extraction Kit (Qiagen) and 
stored at -20oC until ligation. 8E7, 8cE7, 5E7 and 5cE7 were PCR amplified from 
8E7 and 5E7 in Gateway vectors using primers with flanking EcoR1 and Xho1 
restriction enzyme cutting sites (Table C). The PCR reaction buffer included 10X 
Pfx Amplification Buffer, 10 mM dNTP mixture, 50 mM MgSO4, corresponding 0.3 
mM forward and reverse primers, 2 ng plasmid DNA, 1 unit Pfx DNA polymerase 
and DNase free distilled water to bring the reaction volume to 50 uL.  A PCR 
cycle of 15 seconds at 94oC for denaturation, 30 seconds at 54oC for annealing 
and 90 seconds at 68oC for elongation was repeated for 25 cycles. PCR products 
were analyzed by 1% agarose gel and extracted from gel as previously 
described. Purified PCR products were then double digested with EcoR1 and 
Xho1 for 1 hour at 37oC and column purified using QIAquick Gel Extraction Kit 
(Qiagen). The double digested vector and insert (either 8E7, 8cE7, 5E7 or 5cE7) 
were ethanol precipitated with a 1:3 vector:insert molar ratio using 2.5M 
	  	   31	  
ammonium acetate, 20 ug glycogen and 2 volumes of ice cold 95% ethanol was 
added and the mixture was incubated overnight at -20oC.  The vector:insert 
mixture were then span down at 13000 rpm for 30 minutes at 4oC, resuspended 
in 200 uL ice cold 70% ethanol, span down at 13000 rpm for 20 minutes at 4oC. 
The supernatant was aspirated and the DNA pellet was air-dried at room 
temperature. Ligation was performed by resuspending the pellet in ligation buffer 
and water with 1uL T4 DNA ligase (NEB) at 16oC overnight.  The resulting 
plasmids were transformed into XL1-Blue competent E. Coli (Stratagene), plated 
on LB/Ampicillin agar plates and incubated overnight at 37oC. Plasmids were 
isolated from colonies following BioRad Plasmid MiniPrep Kit (BioRad) and 
sequenced for verification (Eurofins MWG). Stock bacterial cultures were 
prepared by mixing 900 uL overnight bacterial stock with 100 uL sterile glycerol 
and stored in -80oC. Plasmids were then transformed into codon plus BL21 
E.Coli and stock cultures were prepared and stored in -80oC as previously 
described. GST-8nE71-42  and GST-5nE71-42 were created using the QuikChange 
Site-Directed Mutagenesis Kit (Stratagene) with GST-8E7 and GST-5E7 as 
template and the corresponding mutagenesis primer pairs (Table B) to insert a 
stop codon at amino acid 43 as previously described.  
 
GST-8E7C91A, GST-8E7LRLFV65AAAA and GST-8E7R66A were generated using 
QuikChange Site-Directed Mutagenesis Kit (Stratagene) with GST-8E7 as a 
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template and the corresponding mutagenesis primer pairs (Table B) as 
previously described. 
 
Table C: Cloning Primers for pGEX-4-T1 
Construct Primers 
GST-8E7 F 5’ GCGCGGATCCATGATTGGTAAAGAGGTCACTGTGC 3’ 
R 5’ GCGCCTCGAGTTATGATCCGCCATGTTTGCAGTTACC 3’ 
GST-8cE7 F 5’ GCGCGGATCCGGACATCGAAAGAACTGTATTC 3’ 
R 5’ GCGCCTCGAGTTATGATCCGCCATGTTTGCAGTTACC 3’  
GST-5E7 F 5’ GCGCGGATCCATGATTGGTAAAGAGGTCACCGTGC 3’ 
R 5’ GCGCCTCGAGTTAGGATCCGTCATGTTTGCAGTTTCC 3’ 
GST-5cE7 F 5’ GCGCGGATCCGGACAACGAAAGGATCTTTTAC 3’ 
R 5’ GCGCCTCGAGTTAGGATCCGTCATGTTTGCAGTTTCC 3’ 
 
Purification of GST Fusion Proteins 
GST-8E7 and GST-5E7 constructs were generated as previously described. 
GST-CRM1 plasmid was kindly provided by Dr. Jorgen Kjems and GST-Nup62N 
(containing amino acids 1-265 of Nup62), GST-Nup62C (containing amino acids 
178-522 of Nup62) and GST-153 (containing amino acids 346-1172 of Nup153) 
plasmids were kindly provided by Dr. Nabeel Yaseen. E. Coli BL21 CodonPlus 
(Agilent Technologies) previously transformed by either GST-8E7, or GST-8cE7, 
or GST-8nE7, or GST-8E7C91A, or GST-5E7, or GST-5cE7, or GST-5nE7 were 
induced with 1mM isopropyl-B-D-thiogalactopyranoside (IPTG) at 37oC for 2 
hours. The proteins were then purified in their native state on glutathione-
Sepharose beads (GE Healthcare) according to a standard GST purification 
procedure. Reduced glutathione was used to elute the proteins from the beads. 
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The elutions were dialyzed in transport buffer (20 mM HEPES-KOH, 110 mM 
potassium acetate, 2mM magnesium acetate, 1mM EGTA, 2mM DTT, protease 
inhibitors aprotinin and leupeptin) and checked for purity and lack of degradation 
by 12% SDS-PAGE and Coomassie Blue staining. After aliquoting, the proteins 
were stored at -80oC until use. The purification of GST-Nup62N, GST-Nup62C, 
GST-Nup153, GST-CRM1, GST, and M9-GST (containing the NLS of hnRNP A1) 
were performed by Rebeca Cardoso following the protocol that was mentioned 
above (Rebeca Cardoso, HPV11 E7 protein interacts with Nup62 and CRM1 
nuclear import receptor).  
 
In vitro Nuclear Import Assay 
GST fusion proteins were purified as previously described and SDS-PAGE gel 
electrophoresis and Coomassie blue staining were used to check that the import 
proteins had similar final concentration (Fig. A; Fig. B). The nuclear import 
assays were carried out as previously described (1, 5, 20, 68, 75). Briefly, 
subconfluent HeLa cells, grown on poly-L-lysine coated glass coverslips for 24 h, 
were permeabilized with 70 ug/uL digitonin for 5 min on ice, and washed with 
cold transport buffer. All import reactions contained an energy regenerating 
system (1 mM GTP, 1mM ATP, 5 mM phosphocreatine, and 0.4 U creatine 
phosphokinase), HeLa cytosol (5 uL) and the different GST-fusion proteins (as 
indicated in the Fig. legends). In the competition experiments 5μg Kap β2 were 
used per assay. The final import reaction volume was adjusted to 20 uL with 
	  	   34	  
transport buffer. For visualization of nuclear import the GST fusion proteins were 
detected by immunofluorescence with an anti-GST antibody. Briefly, cells were 
fixed with 3.7% formaldehyde for 10 minutes on ice and methanol-permeabilized 
for 3 minutes at -20oC. Cells were blocked in 3% bovine serum albumin (BSA) in 
1XPBS with 0.1% Tween for 1 hour at room temperature to reduce the non-
specific binding and then incubated with goat anti-GST primary antibody (GE 
Healthcare) diluted 1:100 in 3% BSA for an hour at room temperature. Cells were 
washed with 1XPBS three times and incubated with FITC conjugated rabbit anti-
goat secondary antibody diluted 1:100 in 3% BSA for 30 minutes at room 
temperature. Following three washes with 1XPBS, coverslips were mounted with 
Vectashield-DAPI mounting medium to identify the nuclei of cells.  Nuclear import 
was analyzed by imaging with confocal microscopy as previously described.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG.B. Analysis of GST fusion proteins for nuclear import assay. GST-8E7 
(1), GST-8nE7 (2), GST-8cE7 (3), GST-5E7 (4), GST-5nE7 (5), GST-5cE7 (6), 
M9-GST (7) and GST (8) were purified by use of Glutathione-Sepharose beads 
from E. coli transformed with the corresponding pGEX plasmid and induced with 
IPTG as previously mentioned. The exact amounts used for import reaction of 
each protein was checked with SDS-PAGE gel electrophoresis and Coomassie 
blue staining. M indicates the protein standard.  
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FIG.C. Analysis of GST-8E7 and its mutants for nuclear import assay. GST-
8E7 (1), GST-8E7C91A (2), GST-8E7LRLFV65AAAAA (3), GST-8E7R66A (4), M9-GST 
(5) and GST (6) were purified by use of Glutathione-Sepharose beads from E. 
coli transformed with the corresponding pGEX plasmid and induced with IPTG as 
previously mentioned. The exact amounts used for import reaction of each 
protein were checked with SDS-PAGE gel electrophoresis and Coomassie blue 
staining. M indicates the protein standard.  
 
 
In vitro Isolation Assays 
Cells grown to 50-70% confluency in 75cm2 flasks were transiently transfected 
with either EGFP- 8E7, or EGFP- 8cE7, or EGFP-5E7, or EGFP-5cE7, or EGFP 
using Fugene 6 Transfection Reagent (Roche Applied Science). Transfection 
mixture containing DNA and Fugene 6 was prepared in serum free DMEM - and 
incubated for 20 minutes at room temperature. Cells media were changed to 
DMEM - before adding transfection mixture. Cells were incubated for 6 hours at 
37oC. After 6 hours, the media was changed for DMEM + and incubated for 
another 16 hours. 24 hours post transfection cells were collected with 
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trypsinization and lysed with 0.001% Triton X-100 in 1XPBS with 5mM EDTA and 
protease inhibitors at 4oC for 30 minutes. Lysates were then spun down at 13000 
rpm for 30 minutes at 4oC to remove cellular debris.  
 
Before performing the isolation assays, GST-Nup62N, GST-Nup62C and GST 
immobilized on glutathione-Sepharose beads were analyzed by SDS-PAGE and 
Coomassie blue staining to ensure the proteins were intact and bound to beads 
at similar levels. Equal amounts of cellular lysates (in volume) containing either 
EGFP-8E7, or EGFP-8cE7, or EGFP-5E7, or EGFP-5cE7, or EGFP as well as 
untransfected HeLa cell lysate were incubated with either GST-Nup62N, or GST-
Nup62C or GST immobilized on glutathione-Sepharose beads for 1 hour at 4oC. 
The beads were then washed three times with transport buffer with protease 
inhibitors and 10% glycerol to prevent non-specific binding and remove unbound 
proteins. The bound proteins were eluted with 1X SDS-sample buffer and 
analyzed by western blot as previously described. To detect bound EGFP-tagged 
proteins 1:5000 diluted anti-EGFP (Clontech) was used as primary antibody and 
1:1500 diluted goat anti-mouse IgG conjugated with HRP was used as secondary 
antibody (Santa Cruz). As a positive control, the binding of Kap β2 to Nup62N 
was checked by incubating untransfected HeLa cell lysate with either GST-
Nup62N, GST-Nup62C or GST. 1:2000 diluted anti-Kap β2 antibody (Santa Cruz) 
was used to detect bound Kap β2.  
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HeLa cell lysates containing the expressed EGFP-8E7, or EGFP- 
8E7LRLFV65AAAAA, or EGFP- 8E7R66A, or EGFP-8cE7, or EGFP- 8cE7LRLFV65AAAAA, 
or EGFP-8cE7R66A, or EGFP-16E7, or EGFP-16E7LRLCV65AAAAA, or EGFP-
16E7R66A, or EGFP-11E7, or EGFP-11E7VRLVV65AAAAA, or EGFP-11E7R66A, or 
EGFP-5E7, or EGFP-5cE7, or EGFP (as a negative control) as well as 
untransfected HeLa cell lysate were prepared as described above and were 
incubated with either GST-Nup62N, or GST-Nup153 or GST immobilized on 
glutathione-Sepharose beads for 1 hour at 4oC. Bound proteins were analyzed by 
immunoblotting with either anti-EGFP antibody or with anti-Kap β2 antibody as 
described previously.  
 
HeLa cell lysates containing the expressed EGFP-8cE7, or EGFP-8cE7C91A, or 
EGFP-8cE7C91A/F79A, or EGFP-8cE7C91A/LLF82AAA, or EGFP-5cE7, EGFP-
16E7NesRev (as a positive control), or EGFP (as a negative control) and 1mM 
GTP-γS were incubated with either GST-CRM1 or GST immobilized on 
glutathione-Sepharose beads for 1 hour at 4oC. Bound proteins were analyzed by 
immunoblotting with anti-EGFP antibody as described previously.  
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Chapter 3 
Characterization of the Nuclear Import Mechanism of  
Cutaneous HPV8 E7 protein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   39	  
Nuclear Import of Cutaneous HPV8 E7 Protein Is Mediated by an NLS 
Located Within Its Zinc-binding Domain 
 
Immunofluorescence studies have shown that HPV16 E7 and HPV11 E7 
oncoproteins are predominantly nuclear when expressed transiently in HaCaT, 
U2OS and HeLa cell lines (5, 33, 43, 59, 62). Research in the Moroianu lab has 
further discovered that HPV16 E7 and HPV11 E7 oncoproteins enter the nucleus 
via a non-classical, Ran dependent, and nuclear import receptor independent 
pathway mediated by their C-terminal zinc-binding domain (5, 26, 75). In order to 
map potential nucleocytoplasmic signals of cutaneous HPV 8E7 protein, 
intracellular localizations of 8E7 and its subdomains were analyzed by in vivo 
transient transfections followed by confocal microscopy (Fig. 1). To prevent 
passive diffusion by increasing the molecular weight of HPV 8E7 protein and to 
avoid the immunostaining step for confocal microscopy imaging, we generated 
plasmids containing EGFP fused to N-terminus of HPV8 E7 protein (EGFP-8E7), 
its N-terminal domain containing the CR1 and CR2 domains (EGFP-8nE7) and 
its C-terminal domain containing the zinc-binding domain (EGFP-8cE7). HeLa 
cells were then transiently transfected with these constructs as well as EGFP 
itself. Confocal fluorescence microscopy analysis revealed that the majority of 
cells expressing EGFP-8E7 were mostly nuclear (Fig. 1, panel A), whereas 
EGFP itself was, as expected, pancellular (Fig. 2). Quantitative analysis 
demonstrated that 76.17% +/- 6.68 % cells expressing EGFP-8E7 displayed 
	  	   40	  
mostly nuclear localization in contrast to 96.05 % +/- 0.84 % pancellular 
localization of EGFP itself (Fig. 2). Analysis of the localization of the EGFP-8E7 
subdomains using confocal fluorescence microscopy showed that similar to the 
full length EGFP-8E7, the EGFP-8cE7 was mostly nuclear in 89.7 % +/- 0.77 % 
of cells (Fig. 1, panel E; Fig. 2). On the other hand, EGFP-8nE7 exhibited a 
pancellular localization in the majority of cells (94.68 % +/- 0.75 %)  (Fig. 1, panel 
B; Fig. 2). Phenotypic distribution results of 4 independent experiments were 
averaged for quantitative analysis (Fig. 2; Table 1). Immunoblot analysis with an 
anti-GFP antibody was also performed to show that all the translated proteins 
were intact and expressed at the correct molecular weight and at similar amounts 
in HeLa cells (Fig. 3). The data suggest that cutaneous HPV8 E7 protein contains 
a potential NLS in the C-terminal domain (cNLS) mediating its nuclear 
localization.  
 
To further analyze the nuclear import mediated by the potential cNLS in vitro 
nuclear import assays were performed using digitonin-permeabilized HeLa cells. 
HPV8 E7 protein is a small 103 amino acid protein that could passively diffuse 
through NPC in monomeric form. To prevent the passive diffusion, we generated 
GST-8E7 and its subdomains that are above the passive diffusion limit. Digitonin-
permeabilized HeLa cells were then incubated with either GST-8E7, GST-8nE7, 
GST-8cE7, M9-GST or GST itself in the presence of either transport buffer or 
HeLa cytosol and nuclear import was detected with an anti-GST antibody (Fig. 4). 
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M9-GST was used as a positive control for nuclear import.  It contains the strong 
NLS of hnRNP A1 that would be recognized by Kapβ2 nuclear import receptor in 
HeLa cytosol to mediate its nuclear import (9, 76, 83). In addition, GST lacking 
any NLS was used as a negative control. Nuclear import assays revealed that 
both GST-8E7 and GST-8cE7 were imported into the nucleus in the presence of 
HeLa cytosol (Fig. 4 panel C and K), whereas GST-8nE7 was not (Fig. 4 panel 
G). As expected, the positive control, M9-GST was imported into the nucleus in 
the presence of HeLa cytosol (Fig. 4, panel O) in contrast to the negative control, 
GST (Fig. 4, panel S). These data together with in vivo transfection results show 
that nuclear import of cutaneous HPV8 E7 is mediated by an NLS located in its 
C-terminal domain.  
 
The cutaneous HPV8 E7 protein, similar to mucosal HPV16 E7 and HPV11 E7 
proteins, does not have a canonical basic NLS sequence to mediate its nuclear 
import via karyopherins. As previously discussed, reports from Moroianu Lab 
using in vivo transfections and in vitro nuclear import assays have shown that 
HPV16 E7 and HPV11 E7 proteins have zinc-binding domains mediating their 
nuclear localizations (5, 26, 57, 75). The C-terminal domain of cutaneous HPV8 
E7 protein also contains a zinc-binding fold consisting of two copies of Cys-X-X-
Cys sequence motif separated by 29 amino acids. To investigate if the integrity of 
zinc-binding domain was essential for HPV8 E7 nuclear localization, zinc-binding 
domain mutants were first created in the context of EGFP-8cE7 using site-
directed mutagenesis (Fig. 5). The intracellular localizations of the resultant 
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mutant proteins were then analyzed in comparison with the wild type via transient 
transfections followed by confocal fluorescence microscopy (Fig. 6; Fig. 7; Table 
2). Each cysteine taking part in zinc coordination and the mutants created are 
shown in Figure 5. The respective cysteines were mutated to alanine to prevent 
folding problems due to their small size and to prevent post-translational 
modifications. Instead of a C61A mutation, a double substitution (CC60AA) was 
created due to another cysteine at position 60, which can potentially substitute for 
the interaction with zinc (Fig. 5). The same principal was applied to create 
CGC56AAA mutant instead of C58A mutant (Fig. 5). This substitution has been 
previously analyzed in the context of both HPV11 E7 and HPV16 E7 (26, 57). 
Confocal microscopy analysis showed that EGFP-8cE7CC60AA (Fig. 6, panel C), 
EGFP-8cE7C91A (Fig. 6, panel E), EGFP-8cE7C91/94A (Fig. 6, panel G), and EGFP-
8cE7CGC56AAA (Fig. 6, panel I) mutants all exhibited pancellular localization in the 
majority of the cells with a small percent of cells having cytoplasmic localization 
(Fig. 7). On the other hand, the majority of EGFP-8cE7 expressing cells showed 
mostly nuclear localization (Fig. 6, panel A). Quantitative analysis of phenotypic 
distribution was performed based on 4 independent experiments and revealed 
that 87.53 % +/- 2.03 % cells expressing EGFP-8cE7CC60AA, 81.17 % +/- 2.66 % 
cells expressing EGFP-8cE7C91A, 86.95 % +/- 4.66 % cells expressing EGFP-
8cE7CC91/94A and 88.20 % +/- 5.67 % cells expressing EGFP-8cE7CGC56AAA were 
pancellular in contrast to nuclear localization of  EGFP-8cE7 in 87.35 % +/- 2.01 
% of cells (Fig. 7; Table 2). These data suggest that the integrity of the zinc-
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binding domain is essential for the efficient nuclear localization of 8cE7.  
 
In order to investigate the effect of cysteine mutations in the intracellular 
localization of the full length HPV8 E7, the same mutants were created in the 
context of EGFP-8E7. The intracellular localizations of the resultant EGFP-8E7 
mutant proteins were analyzed in comparison with the wild type via transient 
transfections followed by confocal fluorescence microscopy (Fig. 8; Fig. 9; Table 
3). Interestingly, a very small reduction in nuclear localization was observed for 
the mutant proteins in comparison with wild type (Fig. 8; Fig. 9). All EGFP-8E7 
cysteine mutants, EGFP-8E7CC60AA (Fig.8, panel C), EGFP-8E7C91A (Fig.8, panel 
E), EGFP-8E7C91/94A (Fig.8, panel G) and EGFP-8E7CGC56AAA (Fig.8, panel I) were 
still mostly nuclear similar to EGFP-8E7 (Fig.8, panel A). Immunoblot analysis 
with an anti-GFP antibody of all the EGFP-8E7 and EGFP-8cE7 mutant proteins 
showed that they were all intact and expressed at similar amounts and at the 
correct molecular weight in HeLa cells (Fig. 10). 
  
To investigate the difference in phenotype distribution between cysteine mutants 
of EGFP-8E7 and EGFP-8cE7, the minimal C91A mutation was created in the 
context of GST-8E7 and its import ability was analyzed by in vitro nuclear import 
assays. Digitonin-permeabilized HeLa cells were incubated with either GST-8E7, 
GST-8E7 C91A, M9-GST, as positive control, or GST, as negative control, in the 
presence or absence of HeLa cytosol and GST fusion protein import was 
	  	   44	  
analyzed with an anti-GST antibody followed by confocal microscopy. GST-8E7 
and M9-GST positive control were both imported into the nuclei in the presence 
of HeLa cytosol (Fig. 11, panel C and K), whereas GST-8E7 C91A and GST 
negative control did not (Fig. 11, panel G and O).  These data show that loss of 
zinc coordination prevents nuclear import of GST-8E7 and confirm that the zinc-
binding domain is essential for the nuclear import of cutaneous HPV8 E7 protein. 
Disruption of zinc coordination can result in loss of E7 dimerization causing 
EGFP-8E7 cysteine mutants to be below the passive diffusion limit. Therefore, 
the mostly nuclear localization of EGFP-8E7 cysteine mutants might be due to 
passive diffusion through the NPC followed by nuclear retention mediated by the 
N-terminal domain of 8E7. Possible HPV8 E7 nuclear targets binding to its N-
terminal domain might explain the difference between pancellular localization of 
EGFP-8cE7 cysteine mutants and mostly nuclear localization of EGFP-8E7 
cysteine mutants.  
 
A Hydrophobic Patch Within The Zinc-binding Domain of Cutaneous HPV8 
E7 Is Responsible for Its Nuclear Localization 
 
Carrier independent translocation of proteins into the nucleus occurs via direct 
interactions between the studied protein and FG nucleoporins  (54, 89). Direct 
non-specific hydrophobic interactions between short hydrophobic patches on the 
surface of karyopherins and the FG nucleoporins are sufficient for the nuclear 
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import of karyopherins through the NPC (67). Previous work from the Moroianu 
lab identified small patches of hydrophobic amino acids within the zinc binding 
domains of HPV11 E7 (65VRLVV69) and HPV16 E7 (65LRLCV69) that are required 
for their nuclear localizations (26, 57). Similar to HPV11 E7 and HPV16 E7 
proteins, HPV8 E7 has also a small hydrophobic patch (65LRLFV69) located in its 
zinc-binding domain with a significant homology to the patches previously 
described. To investigate if this hydrophobic patch of amino acids is essential for 
HPV8 E7 nuclear localization, hydrophobic patch mutants, LRLFV65-69AAAAA, 
were created in the context of both EGFP-8E7 and EGFP-8cE7 using site-
directed mutagenesis (Fig. 12). The LRLFV65-69AAAA mutant is designated 
LRLFV/AAAAA for simplicity. The intracellular localizations of the mutant proteins 
were analyzed in comparison with the wild type via transient transfections 
followed by confocal fluorescence microscopy. Confocal microscopy analysis 
revealed that EGFP-8E7LRLFV/AAAAA (Fig. 13, panel B) and EGFP-8cE7LRLFV/AAAA 
(Fig. 13, panel D) mutants exhibited pancellular localization in the majority of the 
cells in contrast to mostly nuclear localization of both EGFP-8E7 (Fig. 13, panel 
A) and EGFP-8cE7 (Fig. 13, panel C). Quantitative analysis of 4 independent 
experiments revealed that 80.82 % +/- 1.98 % cells expressing EGFP-
8E7LRLFV/AAAAA and 94.88 % +/- 1.29 % cells expressing EGFP-8cE7LRLFV/AAAAA 
had pancellular location in contrast to 87.13 % +/- 1.98 % cells expressing 
EGFP-8E7 and 90.98 % +/- 1.27 % cells expressing EGFP-8cE7 that had 
nuclear localization (Fig. 14; Table 4).   
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The hydrophobic patches of HPV16E7, HPV11 E7 and HPV8 E7 have a 
conserved positively charged arginine at position 66. To investigate the possible 
role of conserved arginine within the hydrophobic patch, R66A mutants were 
generated in the context of both EGFP-8E7 and EGFP-8cE7 (Fig. 12). Transient 
transfections showed that both EGFP-8E7R66A (Fig. 15, panel B) and EGFP-
8cE7R66A (Fig. 15, panel D) mutants had mostly nuclear localizations similar to 
EGFP-8E7 (Fig. 15, panel A) and EGFP-8cE7 (Fig. 15, panel C). Quantitative 
analysis of 5 independent experiments showed that 85.58 % +/- 1.05 % EGFP-
8E7R66A expressing cells exhibited mostly nuclear phenotype similarly as 85.02 % 
+/- 1.29 % EGFP-8E7 expressing cells; also 91.84 % +/- 0.79 % EGFP-8cE7R66A 
expressing cells had mostly nuclear phenotype similarly as 92.5 % +/- 1.50 % 
EGFP-8cE7 expressing cells (Fig. 16; Table 5). Together these data suggest that 
the hydrophobic residues within the zinc-binding domain of HPV8 E7 are 
responsible for the nuclear localization of EGFP-8E7 whereas the positively 
charged arginine 66 has no significant role in the function of cNLS. 
 
To further confirm the role of the hydrophobic patch in nuclear import, the same 
mutations, LRLFV/AAAA and R66A, were created in the context of GST-8E7. In 
vitro nuclear import assays were performed by incubating digitonin-permeabilized 
HeLa cells with either GST-8E7, GST-8E7LRLFV/AAAAA, GST-8E7R66A or GST itself 
in the presence or absence of HeLa cytosol. Nuclear import of GST fusion 
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proteins was detected with an anti-GST antibody (Fig. 17). Nuclear import assay 
showed that both GST-8E7 and GST-8E7R66A were imported into the nucleus in 
the presence of HeLa cytosol (Fig. 17 panel C and K), whereas GST-
8E7LRLFV/AAAAA was not (Fig. 17 panel G). As expected, the negative control, GST 
was not imported into the nucleus in the presence of HeLa cytosol (Fig. 17, panel 
O). These data together with in vivo transfection results further confirm that the 
patch of hydrophobic residues, 65LRLFV69, within the zinc-binding domain of 
cutaneous HPV8 E7 protein is essential for the cNLS function and that the 
positively charged arginine residue at position 66 has no significant role in the 
nuclear import of 8E7.   
 
Cutaneous HPV8 E7 Interacts With The FG Nucleoporins, Nup62 and 
Nup153 Via Its Zinc-binding Domain 
 
As previously discussed, FG nucleoporins facilitate the passage of nuclear 
receptors through the NPC via low affinity non-specific hydrophobic interactions 
(39, 67, 84, 85, 87, 94) and proteins which enter the nucleus independent of 
nuclear import receptors, such as HTLV-1 Tax, MAPK and karyopherin α, can 
specifically and directly bind to nucleoporins, Nup62, Nup214 and Nup153 in 
vitro, respectively (54, 64, 90). Previous work from the Moroianu lab identified 
that hydrophobic patches of HPV11 E7 and HPV16 E7 interact with FG repeats 
of Nup62 to facilitate their nuclear import (26, 57). Since in vivo transfections and 
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in vitro nuclear import assays showed that the patch of hydrophobic residues 
within the zinc-binding domain of cutaneous HPV8 E7 protein is essential for its 
nuclear localization, isolation assays were performed to further investigate the 
actual import mechanism. First, the direct binding between the FG repeats of 
Nup62 and cutaneous HPV8 E7 was investigated. Nup62 interacts with Nup54 
and it is located at the central transport channel of the NPC forming the transport 
channel and interacts with karyopherins via its N-terminal FG repeats (84). HeLa 
cell lysates expressing either EGFP-8E7 or EGFP were incubated with either 
GST-Nup62N, an N-terminal fragment of Nup62 that contains all 6 FG repeats of 
Nup62, GST-Nup62C, lacking any FG repeats or GST which were immobilized 
on glutathione-Sepharose beads. Cell lysates and the eluted bound proteins 
were analyzed by immunoblotting with an anti-GFP antibody. Isolation assays 
showed that EGFP-8E7 directly interacted with GST-Nup62N but not with GST-
Nup62C or GST (Fig. 18, lanes 4, 7 and 10). As expected, EGFP negative control 
failed to bind to any of the GST fusion proteins (Fig. 18, lanes 5, 8 and 11). 
Kapβ2 nuclear import receptor binding to GST-Nup62N but not GST-Nup62C or 
GST was used as a positive control (Fig. 18, lanes 6, 9 and 12). These data 
suggest that cutaneous HPV8 E7 can specifically interact with FG repeats of 
Nup62.  
 
To determine whether this binding involves the zinc-binding domain of cutaneous 
HPV8 E7, isolation assays investigating the interaction between EGFP-8cE7 and 
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Nup62N were performed. HeLa cell lysates expressing either EGFP-8cE7 or 
EGFP were incubated with either GST-Nup62N, GST-Nup62C or GST which 
were immobilized on glutathione-Sepharose beads. Cell lysates and the eluted 
bound proteins were again analyzed by immunoblotting with an anti-GFP 
antibody. EGFP-8cE7 directly bound to GST-Nup62N but to with GST-Nup62C or 
GST (Fig. 19, lanes 4, 7 and 10). As expected, the positive control, Kapβ2 
interacted with GST-Nup62N but not with GST-Nup62C or GST (Fig. 19, lanes 6, 
9 and 12), whereas the negative control EGFP did not bind to either one (Fig. 19, 
lanes 5, 8 and 11). This data indicate that cutaneous HPV8 E7 can specifically 
interact with FG repeats of Nup62 via its zinc-binding domain.  
 
In order to examine the possibility that hydrophobic patch amino acids within the 
zinc-binding domain of cutaneous HPV8 E7 are responsible for the binding to FG 
repeats of Nup62, HeLa cell lysates expressing either EGFP-8E7, EGFP-
8E7LRLFV/AAAA, EGFP-8E7R66A, EGFP-8cE7, EGFP-8cE7LRLFV/AAAA, EGFP-
8cE7R66A or EGFP were incubated with either GST-Nup62N or GST and isolation 
assays were performed as described previously. Significantly, both EGFP-
8E7LRLFV/AAAAA and EGFP-8cE7LRLFV/AAAAA hydrophobic patch mutants failed to 
bind to GST-Nup62N (Fig. 20, lanes 10 and 13). In contrast, their corresponding 
EGFP-8E7R66A and EGFP-8cE7R66A mutants bound to GST-Nup62N (Fig. 20, 
lanes 10, 18, 11 and 19). As expected, EGFP-8E7, EGFP-8cE7 and Kapβ2 
interacted with GST-Nup62N, but not EGFP (Fig. 20, lanes 9, 12, 15 and 16). 
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Any of the EGFP fusion proteins or Kapβ2 bound to GST negative control (Fig. 
20 lanes 17, 18, 19, 20, 21, 22, 23 and 24). Isolation assays in agreement with 
the localization data strongly suggest that the hydrophobic residues, 65LRLFV69, 
within the zinc-binding domain of cutaneous HPV8 E7 protein but not arginine 66 
are essential for hydrophobic interactions between the zinc-binding domain and 
FG repeats of Nup62 mediating the nuclear import of HPV8 E7 protein.  
 
To further confirm the role of the hydrophobic patch in binding to FG repeats, 
cutaneous HPV8 E7 binding to another FG nucleoporin, Nup153 was analyzed 
by in vitro isolation assays. Nup153 has 30 FG repeats and resides primarily on 
the nuclear basket of the NPC and has been shown to interact with karyopherins 
(7). For these isolation assays, recombinant GST-Nup153 (amino acids 346-
1175) containing the zinc finger domains and FG repeats of Nup153 was used. 
HeLa cell lysates expressing either EGFP-8E7, EGFP-8E7LRLFV/AAAA, EGFP-
8E7R66A, EGFP-8cE7, EGFP-8cE7LRLFV/AAAA, EGFP-8cE7 R66A or EGFP were 
incubated with either GST-Nup153 or GST and isolation assays were performed 
as described previously. As expected, the positive control, Kapβ2 bound to GST-
Nup153 but not to GST (Fig. 21, lanes 16 and 24), whereas the negative control 
EGFP did not interact with either one (Fig. 21, lanes 15 and 23). Similar to Nup62 
isolation assay results, both EGFP-8E7 and EGFP-8cE7 as well as their R66A 
mutants, EGFP-8E7R66A and EGFP-8cE7R66A bound to GST-Nup153 but not to 
GST (Fig. 21, lanes 9, 11, 12, 14, 17, 19, 20 and 22). On the other hand, the 
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corresponding hydrophobic patch mutants EGFP-8E7LRLFV/AAAAA and EGFP-
8cE7LRLFV/AAAAA did not interact with either GST-Nup153 or GST (Fig. 21, lanes 
10, 13, 18 and 21). Together these data suggest that cutaneous HPV8 E7 
interacts with Nup153 via its zinc-binding domain and that the hydrophobic 
residues in 65LRLFV69 patch but not the positively charged arginine 66 are 
essential for this interaction.  
 
Previous work from the Moroianu lab has shown that mucosal HPV11 E7 and 
HPV16 E7 interact with FG repeats of Nup62 via their zinc-binding domains and 
that their corresponding hydrophobic patches, 65VRLVV69 and 65LRLCV69, 
respectively are responsible for these interactions (26, 57).  Based on the 
similarities in nuclear import mechanisms between different HPV E7 proteins, the 
interaction between Nup153 and both HPV16 E7 and HPV11 E7 was 
investigated by isolation assays. GST-153 and GST immobilized on glutathione-
Sepharose beads were first incubated with HeLa cells expressing either EGFP-
16E7, EGFP-16E7LRLCV/AAAA, EGFP-16E7R66A or EGFP and cell lysates and 
bound proteins were analyzed by immunoblotting using an anti-EGFP antibody. 
Isolation assay results showed that EGFP-16E7 and EGFP-16E7R66A interacted 
directly with GST-Nup153 but EGFP-16E7LRLCV/AAAA and EGFP did not (Fig. 22, 
lanes 6, 7, 8 and 9). As expected, none of the EGFP fusion proteins bound to 
GST negative control (Fig. 22, lanes 11, 12, 13 and 14) and Kapβ2 positive 
control interacted with GST-Nup153 but not with GST (Fig. 22, lanes 10 and 15). 
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Similar isolation assays were performed to investigate the interaction between 
GST-Nup153 and EGFP-11E7, its hydrophobic mutant, EGFP-11E7 VRLVV/AAAAA 
and its R66A mutant, EGFP-11E7R66A. Significantly, EGFP-11E7 and EGFP-
11E7R66A bound to GST-Nup153 but not to GST (Fig. 23, lanes 6, 8, 11 and 13). 
Moreover, EGFP-11E7VRLVV/AAAAA did not interact either with GST-Nup153 or GST 
(Fig. 23, lanes 7 and 12). As expected, Kapβ2 bound to GST-153 but not to GST 
(Fig. 23, lanes 10 and 15) and EGFP did not interact with either one (Fig. 23, 
lanes 9 and 14).  Together these data indicate that mucosal HPV16 E7 and 
HPV11 E7 proteins also interact with Nup153 via hydrophobic residues within 
their zinc-binding domains. Overall the data suggest that the interaction 
mechanism between HPV E7 proteins and the two FG repeat nucleoporins, 
Nup62 and Nup153, is conserved between HPV types.  
 
Overall the data on the nuclear import of cutaneous HPV8 E7 showed that 8E7 
interacts with Nup62 and Nup153 via hydrophobic interactions. As this 
mechanism of import is similar to that of karyopherins, we tested whether excess 
Kapβ2 would compete for 8E7 import into the nucleus. To investigate the effect of 
this competition on GST-8E7 nuclear import, in vitro nuclear import assays were 
performed in digitonin-permeabilized HeLa cells in the presence of only HeLa 
cytosol or HeLa cytosol plus excess Kapβ2 as previously described (1, 5, 20, 68, 
75). GST-8E7 was imported into the nucleus in the presence of HeLa cytosol 
(Fig. 24, panel A). Interestingly, excess Kapβ2 competed with 8E7 binding to the 
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FG nucleoporins and inhibited its nuclear import (Fig. 24, panel C). M9-GST with 
the NLS of hnRNP A1 that is recognized and imported into the nucleus by Kapβ2 
was used as a positive control. As expected, excess Kapβ2 did not change its 
nuclear import (Fig. 24, panel G). M9-GST was imported into the nucleus in the 
presence of HeLa cytosol as well as HeLa cytosol plus excess Kapβ2 (Fig. 24, 
panels E and G). GST negative control was not imported in the presence of 
either HeLa cytosol or HeLa cytosol plus excess Kapβ2 (Fig. 24, panels I and K). 
 
To further support the role of Nup62 in nuclear import of 8E7, we investigated the 
effect of anti-Nup62 antibody, that specifically recognizes FG repeats of Nup62, 
on the GST-8E7 import into the nucleus. Digitonin-permeabilized HeLa cells were 
incubated with GST-8E7 in the presence of either transport buffer, HeLa cytosol 
or HeLa cytosol plus anti-Nup62 antibody and nuclear import was detected with 
an anti-GST antibody (Fig. 25). As expected, GST-8E7 was imported into the 
nucleus in the presence of HeLa cytosol but not in the presence of transport 
buffer (Fig. 25, panels A and B). Interestingly, anti-Nup62 antibody blocked the 
import of GST-8E7 (Fig. 25, panel C). These data further prove that cutaneous 
HPV8 E7 interacts specifically with the FG repeats of Nup62 to mediate its 
nuclear import.  
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Cutaneous HPV5 E7 and HPV8 E7 Proteins Have Similar Nuclear Import 
Mechanisms 
 
Similar to HPV8 E7, cutaneous HPV5 is specifically linked to malignant lesions 
and actinic keratoses and has been classified as high risk type (3, 11, 24, 59, 65, 
73, 96). Sequence comparison by BLAST between HPV5 E7 and HPV8 E7 
proteins shows that they have 77% sequence similarity and they share common 
motifs. To investigate if HPV5 E7 and HPV8 E7 share the mechanism by which 
they are imported into the nucleus, in vivo transient transfections and in vitro 
nuclear import assays were performed. In order to map potential 
nucleocytoplasmic signals of cutaneous 5E7 protein, intracellular localizations of 
EGFP-tagged 5E7 and its subdomains were first analyzed by in vivo transient 
transfections followed by confocal microscopy. HeLa cells were transiently 
transfected with plasmids containing EGFP fused to N-terminus of HPV5 E7 
protein (EGFP-5E7), its N-terminal domain containing the CR1 and CR2 domains 
(EGFP-5nE7) and its C-terminal domain containing the zinc-binding domain 
(EGFP-5cE7). Confocal fluorescence microscopy analysis showed that the 
majority of cells expressing EGFP-5E7 and EGFP-5cE7 was mostly nuclear (Fig. 
26, panel A and E). Phenotypic distribution results of 5 independent experiments 
were averaged for quantitative analysis (Fig. 27; Table 6). Quantitative analysis 
demonstrated that 76.24 % +/- 6.01 % cells expressing EGFP-5E7 and 82.94 % 
+/- 3.03 % cells expressing EGFP-5cE7 had mostly nuclear localization (Fig. 27). 
	  	   55	  
On the other hand, analysis of the localization of the EGFP-5nE7 revealed that 
the EGFP-5nE7 was mostly pancellular in 88.20 % +/- 1.70 of cells (Fig. 26, 
panel C; Fig. 27). Immunoblot analysis with an anti-GFP antibody was also 
performed to show that all the translated proteins were intact and expressed at 
the correct molecular weight and at similar amounts in HeLa cells (Fig. 28). The 
data suggest that cutaneous HPV5 E7 protein contains a potential cNLS 
mediating its nuclear localization, similar to HPV8 E7.  
 
To further analyze the nuclear import mediated by the potential cNLS in vitro 
nuclear import assays were performed. Digitonin-permeabilized HeLa cells were 
incubated with either GST-5E7, GST-5nE7, GST-5cE7, M9-GST or GST itself in 
the presence of either transport buffer or HeLa cytosol and nuclear import was 
detected with an anti-GST antibody (Fig. 29). As expected, M9-GST positive 
control was imported into the nucleus in the presence of HeLa cytosol (Fig. 29, 
panel O), whereas GST itself was not (Fig. 29, panel S). Nuclear import assays 
showed that both GST-5E7 and GST-5cE7 were imported into the nucleus in the 
presence of HeLa cytosol (Fig. 29 panel C and K), whereas GST-5nE7 was not 
(Fig. 29 panel G). These data together with in vivo transfection results show that 
cutaneous HPV5 E7 nuclear import is mediated by a NLS located in its C-
terminal domain in a similar way to cutaneous HPV8 E7.  
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As cutaneous HPV5 E7 and HPV8 E7 share nuclear import mechanisms, 
isolation assays were performed to investigate first the direct binding between FG 
repeats of Nup62 and HPV5 E7. HeLa cell lysates expressing either EGFP-5E7, 
EGFP-5cE7 or EGFP were incubated with either GST-Nup62N, GST-Nup62C or 
GST which were immobilized on glutathione-Sepharose beads. Cell lysates and 
the eluted bound proteins were analyzed by immunoblotting with an anti-GFP 
antibody. Isolation assays showed that EGFP-5E7 and EGFP-5cE7 specifically 
interacted with GST-Nup62N but not with GST- Nup62C or GST (Fig. 30, lanes 5, 
6, 9, 10, 13 and 14). As expected, EGFP negative control failed to bind to any of 
the GST fusion proteins (Fig. 30, lanes 7, 11 and 15). Kapβ2 binding to GST-
Nup62N but not GST-Nup62C or GST was used as a positive control (Fig. 30, 
lanes 8, 12 and 16). These data suggest that cutaneous HPV5 E7, similar to 
HPV8 E7, can directly interact with FG repeats of Nup62 via its zinc-binding 
domain.  
 
To determine whether there is also a direct binding between cutaneous HPV5 E7 
protein and Nup153, isolation assays were performed. HeLa cell lysates 
expressing either EGFP-5E7, EGFP-5cE7 or EGFP were incubated with either 
GST-Nup153 or GST which were immobilized on glutathione-Sepharose beads. 
Cell lysates and the eluted bound proteins were analyzed by immunoblotting with 
an anti-GFP antibody. Both EGFP-5E7 and EGFP-5cE7 directly bound to GST-
Nup153 but to GST (Fig. 31, lanes 4, 5, 7 and 8). As expected, the positive 
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control, Kapβ2 interacted with GST-Nup153 but not with GST (Fig. 31, lanes 11 
and 12), whereas the negative control EGFP did not bind to either one (Fig. 31, 
lanes 6 and 9). These data indicate that cutaneous HPV5 E7, similar to HPV8 
E7, HPV16E7 and HPV11 E7, can specifically interact with Nup153 via its zinc-
binding domain. Overall these data indicate that cutaneous HPV8 E7 and HPV5 
E7 proteins share the mechanism by which they are imported into the nucleus 
and the interaction mechanism between HPV E7 proteins and the two FG repeat 
nucleoporins, Nup62 and Nup153, is conserved between HPV types.  
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Chapter 4 
Characterization of the Nuclear Export Mechanism of  
Cutaneous HPV8 E7 protein 
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Nuclear Export of Cutaneous HPV8 E7 Is Mediated by CRM1 Nuclear Export 
Receptor 
 
As mentioned previously, CRM1 nuclear export receptor mediates nuclear export 
of cargoes containing leucine rich NESs (29, 39, 63, 85, 94). Previous research 
in the Moroianu lab characterized the leucine rich NES within the zinc-binding 
domains of both HPV16 E7 and HPV11 E7 mediating their nuclear export in a 
CRM1 dependent way (43, 57). The carboxyl terminal domain of cutaneous 
HPV8 E7 protein also contains a leucine rich amino acid sequence.  To 
determine if HPV8 E7 protein has a functional NES, and if CRM1 is involved in its 
nuclear export, a specific chemical inhibitor of CRM1, ratjadone A (RJA) was 
used (60). As a positive control for RJA experiments, EGFP-16E7 carrying the 
strong NES of HIV Rev protein was used. Briefly, 20 hours after transfection with 
EGFP-8E7, EGFP-8nE7, EGFP-8cE7 or EGFP-16E7NesRev, HeLa cells were 
treated for 4 hours with 10ng/mL RJA. The cells were then fixed and analyzed 
using confocal fluorescence microscopy. Quantitative analysis of 5 independent 
experiments showed that as expected, RJA treatment only slightly increased the 
mostly nuclear localization of both EGFP-8E7 and EGFP-8cE7 (Fig. 32; Table 7). 
89.84 % +/- 1.34 % of EGFP-8E7 and 93.46 % +/- 0.46 % of EGFP-8cE7 
expressing cells exhibited a mostly nuclear localization after RJA treatment in 
comparison to 83.26 % +/- 1.56 % of EGFP-8E7 and 90.38 % +/- 1.54 % EGFP-
8cE7 expressing cells in the absence of RJA (Fig. 32; Table 7). RJA treatment 
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did not change the pancellular localization of EGFP-8nE7 (Fig. 32; Table 7). 
EGFP-16E7NesRev plasmid that encodes the 16E7 oncoprotein fused to the strong 
leucine rich NES of HIV-1 Rev protein was used as a positive control (Fig. 32). 
As expected, the localization of translated EGFP-16E7NesRev was cytoplasmic in 
the majority of transfected cells (84.42 % +/- 4.45 %) and the RJA treatment 
resulted in a dramatic re-localization of the EGFP-16E7NesRev fusion protein into 
the nucleus (97.42 % +/- 0.78 %) (Fig. 32).  
 
 
To test whether HPV8 E7 protein has a weak NES that is masked by a stronger 
C-terminal NLS, transient transfections were repeated to investigate the effect of 
RJA on the localization of two EGFP-8cE7 zinc-binding domain mutants, EGFP-
8cE7CC60AA and EGFP-8cE7C91A, which were previously determined to have 
pancellular localizations (Fig. 6, panels C and E).  HeLa cells previously 
transfected with either EGFP-8cE7, EGFP-8cE7CC60AA or EGFP-8cE7C91A were 
treated with RJA as previously described. Quantitative analysis of 5 independent 
experiments showed a change from 89.9 % +/- 2.62 % pancellular localization for 
EGFP-8cE7CC60AA in the absence of RJA to 89.6 % +/- 1.86 % mostly nuclear 
localization in the presence of RJA (Fig. 33, panels E and G; Fig. 34; Table 8). 
Similarly, 88.4 % +/- 1.98 % pancellular localization for EGFP-8cE7C91A in the 
absence of RJA shifted to 88.9 % +/- 2.32 % mostly nuclear localization in the 
presence of RJA (Fig. 33, panels I and K; Fig. 34; Table 8). EGFP-8cE7 mostly 
nuclear localization remained largely unchanged after RJA treatment. However, a 
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small increase was examined in the mostly nuclear percentage (Fig. 33, panels A 
and C; Fig. 34). As expected, mostly cytoplasmic localization of EGFP-16E7NesRev 
control changed to mostly nuclear in the majority of transfected cells after RJA 
treatment (Fig. 34). This data suggest the presence of a weak NES that is 
masked by a stronger NLS in the C-terminal domain of cutaneous HPV8 E7.  
 
RJA experiments were also performed to see the effect of RJA on the localization 
of two EGFP-8E7 cysteine mutants, EGFP-8E7CC60AA and EGFP-8E7C91A, which 
were previously determined to be mostly nuclear (Fig. 8; Fig. 9). 20 hours after 
transfection, HeLa cells expressing either EGFP-8E7, EGFP-8E7CC60AA, EGFP-
8E7C91A or EGFP-16E7NesRev were treated for 4 hours with 10ng/mL RJA and the 
intracellular localization of EGFP fusion proteins were then analyzed using 
confocal fluorescence microscopy. Quantitative analysis of 5 independent 
experiments showed that similar to wild type EGFP-8E7, RJA treatment only 
slightly increased the mostly nuclear localization of both EGFP-8E7CC60AA and 
EGFP-8E7C91A (Fig. 35; Table 9). As expected, in the presence of RJA, EGFP-
16E7NesRev protein was re-localized mostly to the nucleus (Fig. 35; Table 9).  
 
As RJA treatment changed the intracellular localization of EGFP-8cE7 cysteine 
mutants from pancellular to mostly nuclear suggesting a weak NES mediating its 
nuclear export in a CRM1 dependent pathway, isolation assays were performed 
to investigate the direct binding between cutaneous HPV8 E7 and CRM1. As 
	  	   62	  
HPV8 E7 and HPV5 E7 have similar nuclear import mechanisms and cutaneous 
HPV5 E7 has also a leucine rich amino acid sequence within its zinc-binding 
domain similar to HPV8 E7, we also investigated the interaction between EGFP-
5E7 and CRM1 to see if they also share the same nuclear export mechanisms. 
HeLa cell lysates expressing either EGFP-8E7, EGFP-5E7, EGFP-16E7NesRev or 
EGFP were incubated with either GST-CRM1 or GST, which were immobilized 
on glutathione-Sepharose beads. Cell lysates and the eluted bound proteins 
were analyzed by immunoblotting with an anti-GFP antibody. Isolation assays 
showed that EGFP-8E7 and EGFP-5E7 specifically interacted with GST-CRM1 
but not with GST (Fig. 36, lanes 5, 6 9, and 10). As expected, the positive control 
EGFP-16E7NesRev interacted with GST-CRM1 but not with GST (Fig. 36, lanes 7 
and 11). The EGFP negative control failed to bind to any of the GST fusion 
proteins (Fig. 36, lanes, 8 and 12). These data suggest that cutaneous HPV8 E7 
and HPV5 E7 can specifically interact with CRM1.  
 
Similar to HPV16E7, HPV8 E7 protein has possible leucine rich NES sequence 
(76IRTFQELLF84), where bold characters represent amino acids that may be 
important for NES function. To further characterize the NES sequence and the 
necessary amino acids for its proper function, NES mutants were created in the 
context of EGFP-8cE7C91A and their localizations were studied by transient 
transfections. HeLa cells were transfected with EGFP-8cE7, EGFP-8cE7C91A, 
EGFP-8cE7C91A/F79A, EGFP-8cE7C91A/LLF82AAA and their intracellular localizations 
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were observed under confocal fluorescent microscopy (Fig. 37). As expected, 
majority of cells expressing EGFP-8cE7 had mostly nuclear localization (Fig. 37, 
panel A).  On the other hand, EGFP-8cE7C91A exhibited pancellular localization 
(Fig. 37, panel B). Initially, the resultant NES double mutant proteins, EGFP-
8cE7C91A/F79A, EGFP-8cE7C91A/LLF82AAA, had expression problems in HeLa cells. 
Due to possible misfolding and aggregation, high fluorescent intensity 
cytoplasmic clumps were observed in the majority of cells expressing EGFP-
8cE7C91A/F79A and EGFP-8cE7C91A/LLF82AAA (data not shown). Thus, the 
intracellular localization of both EGFP-8cE7C91A/F79A and EGFP-8cE7C91A/LLF82AAA 
was mostly cytoplasmic (data not shown). As we repeated the transfections using 
lower concentration of plasmids to decrease expression levels of the mutant 
proteins and using new batch of HeLa cells, we were able to overcome the 
expression problem. Transient transfections showed that the localization of both 
EGFP-8cE7C91A/F79A and EGFP-8cE7C91A/LLF82AAA double mutants was changed in 
comparison with that of EGFP-8cE7C91A, which had a pancellular localization in 
73% +/- 1.5 % of transfected cells (Fig. 37, panel B, C and D; Fig. 38). 
Quantitative analysis of 4 independent experiments showed that 86.75 % +/- 2.63 
% of EGFP-8E7C91A/F79A and 87.97 % +/- 1.82 % of EGFP-8cE7C91A/LLF82AAA 
expressing cells exhibited mostly nuclear localization similarly as 90.8 % +/- 1.39 
% of EGFP-8cE7 expressing cells (Fig. 38). These data suggest that cutaneous 
HPV8 E7 has a functional leucine rich NES within its C-terminal domain.  
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As EGFP-8cE7C91A/F79A and EGFP-8cE7C91A/LLF82AAA proteins had mostly nuclear 
localization in HeLa cells, in vitro isolation assays were performed to investigate 
the direct interaction between two NES mutants, EGFP-8cE7C91A/F79A and EGFP-
8cE7C91A/LLF82AAA, and GST-CRM1. In these experiments either GST-CRM1 or 
GST, as a negative control, was immobilized on glutathione-Sepharose beads 
and incubated with HeLa cell lysates expressing either EGFP-8cE7, EGFP-
8cE7C91A, EGFP-8cE7C91A/F79A, EGFP-8cE7C91A/LLF82AAA or EGFP. Cell lysates and 
the eluted bound proteins were analyzed via immunoblotting with an anti-EGFP 
antibody. EGFP-8cE7 and EGFP-8cE7C91A bound to GST-CRM1 but not to GST 
(Fig. 39, lanes 6, 7, 11 and 12).  Interestingly, EGFP-8cE7C91A/F79A and EGFP-
8cE7C91A/LLF82AAA did not interact with either GST-CRM1 or GST (Fig. 39, lanes 8, 
9, 13 and 14). As expected, EGFP did not bind to either one (Fig 39, lanes 10 
and 15). Overall, these data suggest that cutaneous HPV8 E7 has a functional 
leucine rich NES within its C-terminal domain mediating its export in a CRM1 
dependent way.  
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Chapter 5 
Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   66	  
High risk mucosal HPVs are now well accepted to be the predominant cause of 
anogenital cancers (17, 48, 59, 62, 65, 102). Many studies on the role of HPVs in 
altered host cell growth and immortalization have characterized the E6 and E7 
proteins of high risk HPVs as major transforming proteins (48, 58, 59, 62, 65, 66, 
103). HPVs were first implicated in the development of NMSC in patients with the 
rare autosomal recessive disorder EV (3, 31, 34, 35, 102).  These HPVs, later 
classified as cutaneous HPVs, have also been found in NMSCs of both 
immunocompetent and immunocompromised patients, as well as in healthy skin 
(3, 12, 14, 24, 28, 35, 51, 65, 73). To date, the role of high risk cutaneous HPVs, 
HPV8 and HPV5, in carcinogenesis is not clearly understood, since cutaneous 
HPVs seem to alter molecular mechanisms of the host cell differently than well-
studied mucosal HPVs (102).  
 
Already the most common malignancies in fair-skinned populations worldwide, 
constituting 29% of all cancers, the incidence of NMSCs continues to rise rapidly 
(3, 22, 28, 73). In the United States, over a million patients are diagnosed every 
year with NMSC, including basal cell carcinoma and squamous cell carcinoma, 
with an estimated annual cost of treatment exceeding $500 million (3, 73). 
Although cumulative sun exposure is the most common environmental factor for 
NMSC, cutaneous high risk HPV8 and HPV5 are specifically linked to the 
development of NMSC in both immunocompromised and immunocompetent 
patients (3, 11, 24, 30, 34, 58, 65, 73, 102). To further understand the function of 
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cutaneous HPV8 E7 protein in the viral life cycle and transformation of the host 
cell, it is important to investigate its intracellular localization and its mechanism of 
nucleocytoplasmic trafficking. Therefore, in this study, we investigated the 
nuclear import and export pathways of cutaneous HPV8 E7 protein.  
 
Transient transfections in HeLa cells with EGFP fusion plasmids containing 8E7 
and its subdomains and nuclear import assays in digitonin-permeabilized HeLa 
cells using GST fusion proteins showed an NLS located in C-terminal domain of 
cutaneous HPV8 E7 protein that mediates its nuclear localization and import. As 
previously mentioned, the C-terminal domain of HPV E7 contains a zinc-binding 
domain that is composed of two Cys-X-X-Cys motifs, separated by approximately 
30 amino acids, responsible for the dimerization of E7 protein and its association 
with multiple cellular targets (8, 18, 48, 56, 59, 78, 91, 103). In addition, the zinc-
binding domain is conserved between the E7 proteins of different HPV types (8, 
18, 48, 56, 59, 78, 91, 103). Research in the Moroianu lab previously discovered 
that the zinc-binding domains of mucosal high risk HPV16 E7 and low risk 
HPV11 E7 oncoproteins are essential for cNLS function (26, 57). Here, the role of 
zinc-binding domain of cutaneous HPV8 E7 protein on cNLS function was 
investigated via transient transfection assays with EGFP-8E7, EGFP-8cE7 and 
their corresponding cysteine mutants. We found that site-directed mutagenesis of 
cysteines taking part in zinc coordination to alanine changes the mostly nuclear 
localization of EGFP-8cE7 to pancellular in majority of the cells. These data 
	  	   68	  
strongly suggests that an intact zinc-binding domain is critical for the nuclear 
localization of cutaneous HPV8 E7.  
 
Interestingly, in the context of full length HPV8 E7, only a very small reduction in 
nuclear localization was observed for cysteine mutants in comparison with wild 
type. Immunoblot analysis showed that all mutant proteins were intact and 
expressed at the similar amounts and at the correct molecular weight in HeLa 
cells. We created the minimal C91A mutation in the context of GST-8E7 and 
investigated its ability to import using nuclear import assays. As C91A mutant 
failed to import into the nucleus, we concluded that loss of zinc coordination 
prevents nuclear import of GST-8E7 and that zinc-binding domain is essential for 
the nuclear import of cutaneous HPV8 E7 protein. As previously mentioned, the 
integrity of zinc-binding domain is important for E7 dimerization (18). In addition, 
EGFP-8E7 and its cysteine mutants are only slightly above the passive diffusion 
limit. Previous research in the Moroianu lab showed that disruption of the zinc-
binding domain in the context of EGFP-16E7 was able to shift localization from 
mostly nuclear to pancellular but was not sufficient to prevent the mutants from 
gaining entry to the nucleus (26). On the other hand, 2XEGFP-16E7 zinc-binding 
domain mutants exhibited mostly cytoplasmic localization showing that 
pancellular localization of EGFP-16E7 cysteine mutants was due to passive 
diffusion across the NPC and an intact zinc-binding domain is essential for the 
function of its cNLS (26). Therefore, mostly nuclear localization of EGFP-8E7 
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cysteine mutants might be due to passive diffusion through the NPC followed by 
nuclear retention mediated by the N-terminal domain of 8E7. Cutaneous HPV8 
E7 has many nuclear targets that bind to its N-terminal domain such as pRB and 
its pocket proteins, p107 and 130 (48, 59, 65, 74, 103).  Passive diffusion 
followed by nuclear retention might explain the difference between pancellular 
localization of EGFP-8cE7 cysteine mutants and mostly nuclear localization of 
EGFP-8E7 cysteine mutants. In addition, we can speculate that a more dramatic 
change in intracellular localization would have been observed if 2XEGFP 
constructs were analyzed. Overall, we found that the integrity of cutaneous HPV8 
E7 zinc-binding domain is essential for the cNLS function similar to mucosal 
HPV16 E7 and HPV11 E7.  
 
As previously mentioned, carrier independent translocation of proteins into the 
nucleus occurs via direct interactions between the studied protein and FG 
nucleoporins (54, 89). For instance, nuclear import of HTLV-1 Tax protein is 
carrier independent and mediated by interactions between its zinc-binding 
domain and the FG nucleoporin, Nup62 (90).  In addition, a previous study has 
demonstrated that direct non-specific hydrophobic interactions between short 
hydrophobic patches on the surface of karyopherins and the FG nucleoporins are 
sufficient for the nuclear import of karyopherins through the NPC (67). 
Significantly, the zinc-binding domains of HPVs are rich in non-polar hydrophobic 
amino acids. Previous work from the Moroianu lab found that small hydrophobic 
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patches of amino acids within the zinc-binding domains of mucosal HPV11 E7 
(65VRLVV69) and HPV16 E7 (65LRLCV69) are responsible for their nuclear import 
via hydrophobic interactions with the FG nucleoporin Nup62 (26, 57). The 
65LRLFV69 hydrophobic patch located within the zinc-binding domain of 
cutaneous HPV8 E7 has a significant homology to those of mucosal HPV11 E7 
and HPV16 E7. In this study, the investigation of the intracellular localization of 
hydrophobic patch mutants via transient transfections showed that 65LRLFV69 
within the zinc-binding domain of cutaneous HPV8 E7 is essential for nuclear 
localization of both EGFP-8E7 and EGFP-8cE7. In addition, nuclear import 
assays in agreement with transient transfections further confirmed the role of the 
hydrophobic patch in the nuclear import of GST-8E7. Interestingly, the 
hydrophobic patches of many different HPVs including HPV16 E7, HPV11 E7 
and HPV8 E7, have a conserved positively charged arginine at position 66. In 
this study, we also investigated the possible role of arginine 66 in cNLS function 
via transient transfections and nuclear import assays and showed that the 
positively charged arginine residue has no significant role in the nuclear 
localization and nuclear import of HPV8 E7. A recent paper found that arginine 
66 is necessary for interaction between GTPase activating protein p190 and E7 
proteins of 14 different HPV types including HPV16 and HPV11.  As this 
interaction may have important biological consequences related to actin 
organization of infected cell and these changes could be an important contributor 
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to the viral-life cycle, it can explain the conservation of arginine 66 among 
different HPV E7 proteins (88).  
 
As previously discussed, hydrophobic FG nucleoporins facilitate the passage of 
karyopherins through the NPC via low affinity non-specific hydrophobic 
interactions (39, 67, 84, 85, 87, 94). In addition, proteins, which enter the nucleus 
independent of nuclear import receptors can specifically and directly bind to 
nucleoporins (54, 64, 90). In this study, we found that the hydrophobic residues, 
65LRLFV69, within the zinc-binding domain of cutaneous HPV8 E7 protein but not 
arginine 66 are essential for hydrophobic interactions with FG repeats of Nup62 
mediating the nuclear import of HPV8 E7. Furthermore, we showed that 
cutaneous HPV8 E7 protein directly binds to Nup153 via its zinc-binding domain 
and mutations of hydrophobic residues in 65LRLFV69 to alanines but not 
conserved arginine 66 prevent this interaction. In vitro nuclear import assays in 
the presence of excess Kapβ2 competing with HPV8 E7 nuclear import further 
demonstrated that the import mechanism of HPV8 E7 is similar to that of 
karyopherins. Interestingly, anti-Nup62 antibody that specifically recognizes FG 
repeats of Nup62 blocked the import of GST-8E7. These data were expected 
since Nup62 is located at the central transport channel and interacts with HPV8 
E7 before Nup153, which is located at the nuclear basket of NPC (7, 84). Overall 
these data strongly indicate that nuclear import of cutaneous HPV8 E7 protein is 
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mediated via multiple hydrophobic interactions between the zinc-binding domain 
of HPV8 E7 and FG nucleoporins, Nup62 and Nup153.  
 
As mentioned before, previous work from the Moroianu lab has shown that 
mucosal HPV11 E7 and HPV16 E7 interact with FG repeats of Nup62 via their 
zinc-binding domains and that their corresponding hydrophobic patches, 
65VRLVV69 and 65LRLCV69, respectively are responsible for these interactions (26, 
57). Here, we further showed that mucosal HPV16 E7 and HPV11 E7 proteins 
also interact with Nup153 via hydrophobic residues within their zinc-binding 
domains suggesting that the interaction mechanism between HPV E7 proteins 
and FG repeat nucleoporins, Nup62 and Nup153, is conserved between HPV 
types. Moreover, as transient transfections and nuclear import assays indicated 
that cutaneous high risk HPV5 E7 protein contains a cNLS mediating its nuclear 
localization and nuclear import, isolation assays were performed to further 
investigate its nuclear import mechanism. These experiments showed that HPV5 
E7, similar to HPV8 E7, HPV16 E7 and HPV11 E7, directly interacts with FG 
repeats of Nup62 and Nup153 via its zinc-binding domain. Together these data 
indicate that cutaneous HPV8 E7 and HPV5 E7 and mucosal HPV16 E7 and 
HPV11 E7 proteins share the mechanism by which they are imported into the 
nucleus and that the interaction mechanism between HPV E7 proteins and the 
two FG repeat nucleoporins, Nup62 and Nup153, is conserved between HPV 
types.  
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The FG repeats of Nup62, Nup153 and several other NPC proteins are natively 
unfolded and provide docking sites for cargo-transport receptor complexes in 
transit through the NPC while at the same time serving as barrier against passive 
diffusion (39, 67, 84, 85, 87, 94). Karyopherin mediated nuclear transport 
pathways are known to strongly determine the subcellular localization of majority 
of proteins with classical NLSs (63, 85). In contrast, nuclear proteins lacking 
classical NLSs have shown to enter nucleus via direct interactions with FG 
nucleoporins (54, 64, 90). β-catenin interacts with FG nucleoporins via its 
Armadillo repeats (93). The SMAD family of tumor suppressor proteins, SMAD3 
and SMAD4, bind to FG repeats of Nup214 (96). Direct interactions with Nup62 
and Nup153 have been described for Ets family transcription factor, PU.1 to 
mediate its nuclear import (101). As previously mentioned, MAPK and 
karyopherin α, specifically interact with nucleoporins, Nup214 and Nup153, 
respectively (54, 64).  
 
To replicate efficiently, viruses require a large nucleocytoplasmic trafficking 
capacity. Therefore, they find mechanisms either to promote viral protein 
trafficking or to shut down unnecessary host protein transport pathways or both 
(46). Several viruses interfere with nucleocytoplasmic transport via the 
degradation or disruption of nucleoporins. In particular, Nup62 is cleaved by 
enterovirus protease 2A, hyperphosphorylated by cardiovirus L protein, and 
displaced from the NPC upon adenovirus or HIV-1 infection (19). Herpes simplex 
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virus interferes with host nuclear transport pathway by binding directly to Nup62 
and blocking nuclear import of proteins via Kapα/β1 and Kapβ2 nuclear import 
pathways (98).  
 
In contrast to nuclear import via karyopherins, many viruses also evolved the 
mechanism to directly interact with FG nucleoporins to mediate their carrier 
independent import without competing with many host proteins. For instance, 
HIV1 capsid interacts with FG repeats of Nup153 via hydrophobic interactions to 
facilitate its nuclear import (53). As mentioned before, the Tax protein of HTLV-1 
also enters the nucleus via direct hydrophobic interactions of its zinc-binding 
domain with FG repeats of Nup62 at NPC (90). Furthermore, Herpes simplex 
virus ICP27 protein directly interacts with Nup62 complex at NPC to support 
ICP27 mediated transport of its partners (49) and Epstein-barr virus protein 
kinase BGLF4 binds to Nup62 and Nup153 to mediate its nuclear import in a 
carrier-independent pathway (16).  In this study we were able to characterize the 
carrier independent nuclear import of cutaneous HPV8 E7 protein, which also 
lacks a classical nuclear localization signal. In contrast to carrier dependent 
import, HPV8 E7 protein interacts specifically with the FG repeat nucleoporins, 
Nup62 and Nup153 via hydrophobic interactions between FG repeats and its 
hydrophobic patch.  
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This conserved mechanism of import among different HPV E7 proteins is unique 
compared to other HPV proteins. Previous work from the Moroianu lab showed 
that the HPV16 E6 oncoprotein binds to Kapα adopter, Kapβ1 and Kapβ2 import 
receptors via its C-terminal NLS (47). L2 minor capsid proteins of HPV16, HPV18 
and HPV11 interact with different karyopherins via their NLSs and can enter the 
nucleus via several import pathways mediated by Kapα2β1 heterodimers, Kapβ2, 
and Kapβ3 (10, 20, 42,). The HPV11 major capsid protein L1 binds to the Kapα2 
adapter and enters the nucleus via a Kapα2β1 mediated pathway. In addition, 
HPV11 L1 major capsid protein binds to Kapβ2 and Kapβ3 to disrupt nuclear 
import through these pathways (69, 70). At this time, we can only speculate why 
HPV E7 proteins use a different karyopherin independent mechanism than other 
HPV proteins. As many classical nuclear localization signal carrying cargoes 
need nuclear import receptors to enter nucleus and as HPV11 L1 blocks the 
nuclear import mediated by Kapβ2 and Kapβ3, one possibility may be that E7 
major transforming proteins do not need to compete for import receptors with 
other cellular cargoes. It has been shown that HTLV-1 Tax that has a carrier 
independent pathway is capable of mediating the nuclear import of cellular 
protein NF-kB p65 subunit. Therefore, by altering cellular protein distribution 
HTLV may deregulate cellular processes (93). In addition, Herpes Simplex Virus 
ICP27 mediates nuclear transport of its partners by directly interacting with 
Nup62 (49). Another possibility for carrier independent nuclear import of HPV E7 
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proteins may be to act as transporters for cellular proteins similar to Tax and 
ICP27.  
Here, in addition to the nuclear import mechanism of cutaneous HPV8 E7, we 
also investigated its nuclear export mechanism. Previous research from the 
Moroianu lab characterized the leucine rich NESs in the C-terminal domains of 
mucosal HPV16 E7 (76IRTLEDLLM84) and HPV11 E7 (76IRQLQDLLL84) (43, 57).  
Examination of the C-terminal domain of cutaneous HPV8 E7 protein also 
showed the presence of a possible NES sequence (76IRTFQELLF84), that has a 
high degree of homology with the previously characterized NES sequences of 
HPV16 E7 and HPV11 E7. As the wild type HPV8 E7 and 8cE7 exhibit a nuclear 
localization, RJA treatment only slightly increased the percent of their nuclear 
localization. However, mostly pancellular localizations of two EGFP-8cE7 
cysteine mutants (CC60AA and C91A) changed to mostly nuclear in the 
presence of RJA. This showed that HPV8 E7 protein has a weak NES that is 
recognized by CRM1 nuclear export receptor and it is compensated by a stronger 
C-terminal NLS. The two NES mutants (F79A and LLF82AAA) rescued the 
mostly nuclear localization of a zinc-binding deficient mutant (C91A) preventing 
nuclear export. Previous research in the Moroianu lab discovered the binding 
between CRM1 and the C-terminal domains of HPV16 E7 and HPV11 E7 
proteins (57). Here, isolation assays strongly indicated that cutaneous HPV8 E7 
specifically interacts with CRM1 via its NES located within the C-terminal domain 
and the two NES mutants fail to bind to CRM1. Examination of the intracellular 
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localization of two other minimal NES mutants in the context of EGFP-8E7C91A, 
I76A and L82A, is now used to further characterize the cutaneous HPV8 E7 NES 
sequence. Preliminary data suggest that both EGFP-8E7C91A/I76A and EGFP-
8E7C91A/L82A localize mostly in the nucleus with a nuclear percentage similar to 
EGFP-8cE7 (data not shown). In addition, these new NES mutants fail to bind to 
CRM1 (data not shown) in a way similar to NES mutants, EGFP-8E7C91A/F79A and 
EGFP-8E7C91A/LLf82AAA.  
 
Overall these studies show that cutaneous HPV8 E7 shuttles between the 
nucleus and cytoplasm in a way similar to mucosal HPV16 E7 and HPV11 E7. In 
addition, although mostly nuclear, HPV8 E7 protein localizes both in the 
cytoplasm and in the nucleus, and neither RJA experiments, nor zinc-binding 
domain mutants, made its localization exclusively nuclear or cytoplasmic 
suggesting retention in both compartments via interactions with target proteins.  
 
In summary, nuclear import of HPV8 E7 protein is mediated by an NLS located 
within its zinc-binding domain and the mostly hydrophobic patch within this zinc-
binding domain is responsible for the nuclear localization and nuclear import of 
HPV8 E7 via direct hydrophobic interactions with FG nucleoporins, Nup62 and 
Nup153. In addition, 8E7 has a functional leucine rich NES within its zinc-binding 
domain mediating its export in a CRM1 dependent way.  
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FIG. 1. EGFP-8E7 and EGFP-8cE7 are predominantly nuclear in HeLa cells. 
HeLa cells expressing either EGFP-8E7 (panels A and B), EGFP-8nE7 (panels C 
and D) or EGFP-8cE7 (panels E and F) were fixed 24 hours after transfection 
and examined by confocal microscopy. EGFP fluorescence is shown in the top 
row (panels A, C and E), while DAPI staining of the nuclei is shown in the bottom 
row (panels B, D and F).  	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FIG. 2. Quantitative analysis of the intracellular localization of EGFP-8E7 
and its subdomains. Cells transfected with either EGFP-8E7, EGFP-8nE7, 
EGFP-8cE7 or EGFP were phenotyped as having either mostly nuclear (blue 
bars) or pancellular (red bars) and the quantitative analysis of 4 experiments is 
represented graphically.  	  	  	  	  	  	  	  	  
Table 1: Quantitative analysis of the intracellular localization of EGFP-8E7 
and its subdomains 
 
n=4 # Nuclear # Pancellular # Cytoplasmic 
8E7 440 129 0 
8nE7 27 474 0 
8cE7 464 53 0 
EGFP 16 404 0 
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FIG.3. EGFP-8E7 and its subdomains are well expressed in HeLa cells. 
HeLa cells expressing either EGFP- 8E7 (lane1), EGFP-8nE7 (lane 2), EGFP-
8cE7 (lane 3) or EGFP (lane 4) were analyzed by immunoblotting with an anti-
GFP antibody 24 hours post transfection.  	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FIG. 4. GST-8E7 and GST-8cE7 are imported into the nuclei of digitonin- 
permeabilized HeLa cells. Digitonin-permeabilized HeLa cells were incubated 
with either GST-8E7 (panels A, B, C and D), GST-8nE7 (panels E, F, G and H), 
GST-8cE7 (panels I, J, K and L), M9-GST (panels M, N, O and P) or GST (panels 
Q, R, S and T) in the presence of only transport buffer (panels A, E, I, M and Q) 
or HeLa cytosol (panels C, G, K, O and S). Detection of the localization of the 
GST fusion proteins was performed with an anti-GST antibody. Panels A, C, E, 
G, I, K, M, O, Q and S show the protein localization and panels B, D, F, H, J, L, 
N, P, R and T show the DAPI staining of the nuclei.  
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FIG. 5. Schematic overview of the zinc-binding domain mutants 	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FIG. 6. Mutations of cysteine residues involving the zinc coordination 
change the nuclear localization of EGFP-8cE7. HeLa cells expressing either 
EGFP-8cE7 (panels A and B), EGFP-8cE7CC60AA (panels C and D), EGFP-
8cE7C91A (panels E and F), EGFP-8cE7C91/94A (panels G and H) and EGFP-
8cE7CGC56AAA (panels I and J) were fixed 24 hours after transfection and 
examined by confocal microscopy. Panels A, C, E, G and I represent EGFP 
fluorescence, while panels B, D, F, H and J represent DAPI staining of the nuclei.  
	  	   92	  
	  
	  
	  
	  
	  
FIG. 7. Quantitative analysis of the intracellular localization of cysteine 
mutants in comparison with wild type EGFP-8cE7. Cells transfected with 
either EGFP-8cE7, EGFP-8cE7CC60AA, EGFP-8cE7C91A, EGFP-8cE7C91/94A  or 
EGFP-8cE7CGC56AAA were phenotyped as having either mostly nuclear (blue 
bars),  pancellular (red bars) or mostly cytoplasmic (green bars) and the 
quantitative analysis of 4 experiments is represented graphically.  	  	  	  	  	  
Table 2: Quantitative analysis of the intracellular localization of EGFP-8cE7 
and its zinc-binding domain mutants 
 
n=4 # Nuclear # Pancellular # Cytoplasmic 
8cE7 563 81 0 
8cE7 CC60AA 0 436 63 
8cE7 C91A 53 513 68 
8cE7 C91/94A 0 424 63 
8cE7 CGC56AAA 0 344 46 
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FIG. 8. Mutations of cysteine residues involving the zinc coordination do 
not change the nuclear localization of EGFP-8E7. HeLa cells expressing 
either EGFP-8E7 (panels A and B), EGFP-8E7CC60AA (panels C and D), EGFP-
8E7C91A (panels E and F), EGFP-8E7C91/94A (panels G and H) and EGFP-
8E7CGC56AAA (panels I and J) were fixed 24 hours after transfection and examined 
by confocal microscopy. Panels A, C, E, G and I represent EGFP fluorescence, 
while panels B, D, F, H and J represent DAPI staining of the nuclei. 
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FIG. 9. Quantitative analysis of the intracellular localization of cysteine 
mutants in comparison with wild type EGFP-8E7. Cells transfected with either 
EGFP-8E7, EGFP-8E7CC60AA, EGFP-8E7C91A, EGFP-8E7C91/94A  or EGFP-
8E7CGC56AAA were phenotyped as having either mostly nuclear (blue bars),  
pancellular (red bars) or mostly cytoplasmic (green bars) and the quantitative 
analysis of 7 experiments is represented graphically. 
	  
	  
	  
	  
	  
Table 3: Quantitative analysis of the intracellular localization of EGFP-8E7 
and its zinc-binding domain mutants 
 
n=7 # Nuclear # Pancellular # Cytoplasmic 
8E7 878 254 0 
8E7 CC60AA 918 405 0 
8E7 C91A 758 290 0 
8E7 C91/94A 713 299 0 
8E7 CGC56AAA 754 403 0 
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FIG. 10. The cysteine mutants of both EGFP-8E7 and EGFP-8cE7 are well 
expressed in HeLa cells. HeLa cells expressing either EGFP- 8E7 (lane1), 
EGFP-8E7CC60AA (lane 2), EGFP-8E7C91A (lane 3), EGFP-8E7C91/94A (lane 4), 
EGFP-8E7CGC56AAA (lane 5), EGFP- 8cE7 (lane 6), EGFP-8cE7CC60AA (lane 7), 
EGFP-8cE7C91A (lane 8), EGFP-8cE7C91/94A (lane 9), EGFP-8cE7CGC56AAA (lane 
10) and EGFP (lane 11) were analyzed by immunoblotting with an anti-GFP 
antibody 24 hours post transfection.  	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FIG. 11. The C91A mutation disrupts the nuclear import of GST-8E7 into the 
nuclei of digitonin-permeabilized HeLa cells. Digitonin-permeabilized HeLa 
cells were incubated with either GST-8E7 (panels A, B, C and D), GST-8E7C91A 
(panels E, F, G and H), M9-GST (panels I, J, K and L) or GST (panels M, N, O 
and P) in the presence of only transport buffer (panels A, E, I and M) or HeLa 
cytosol (panels C, G, K and O). Detection of the localization of the GST fusion 
proteins was performed with an anti-GST antibody. Panels A, C, E, G, I, K, M and 
O show the protein localization and panels B, D, F, H, J, L, N and P show the 
DAPI staining of the nuclei.  	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FIG. 12. Schematic overview of the hydrophobic patch and R66A mutants 	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FIG. 13.  Mutations of hydrophobic residues within the zinc-binding domain 
disrupt the nuclear localization of EGFP-8E7 and EGFP-8cE7. HeLa cells 
expressing either EGFP-8E7 (panels A and E), EGFP-8E7 LRLFV/AAAAA (panels B 
and F), EGFP-8cE7 (panels C and G) or EGFP-8cE7 LRLFV/AAAAA  (panels D and 
H) were fixed 24 hours after transfection and examined by confocal microscopy. 
EGFP fluorescence is shown in the top row (panels A, B, C and D), while DAPI 
staining of the nuclei is shown in the bottom row (panels E, F, G and H).  	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FIG. 14.  Quantitative analysis of the effect of the mutation of hydrophobic 
residues within the zinc-binding domain on the localization of both EGFP-
8E7 and EGFP-8cE7. Cells transfected with either EGFP-8E7, EGFP-8E7 
LRLFV/AAAAA, EGFP-8cE7 or EGFP-8cE7 LRLFV/AAAAA  were phenotyped as having 
either mostly nuclear (blue bars),  pancellular (red bars) or mostly cytoplasmic 
(green bars) and the quantitative analysis of 4 experiments is represented 
graphically.  	  	  	  	  
Table 4: Quantitative analysis of the intracellular localization of 
hydrophobic residue mutants in the context of both EGFP-8E7 and EGFP-
8cE7 
 
n=4 # Nuclear # Pancellular # Cytoplasmic 
8E7 858 124 0 
8E7 LRLFV/AAAAA 193 807 0 
8cE7 723 72 0 
8cE7 LRLFV/AAAAA 41 786 0 
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FIG. 15.  Arginine 66 located within the hydrophobic patch does not play a 
role in the nuclear localization of EGFP-8E7 and EGFP-8cE7. HeLa cells 
expressing either EGFP-8E7 (panels A and E), EGFP-8E7 R66A (panels B and F), 
EGFP-8cE7 (panels C and G) or EGFP-8cE7 R66A (panels D and H) were fixed 24 
hours after transfection and examined by confocal microscopy. EGFP 
fluorescence is shown in the top row (panels A, B, C and D), while DAPI staining 
of the nuclei is shown in the bottom row (panels E, F, G and H).  	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FIG. 16.  Quantitative analysis of the effect of R66A mutation within the 
hydrophobic patch on the localization of both EGFP-8E7 and EGFP-8cE7. 
Cells transfected with either EGFP-8E7, EGFP-8E7 R66A , EGFP-8cE7 or EGFP-
8cE7 R66A  were phenotyped as having either mostly nuclear (blue bars),  
pancellular (red bars) or mostly cytoplasmic (green bars) and the quantitative 
analysis of 5 experiments is represented graphically.  
 
 
 
 
 
Table 5: Quantitative analysis of the intracellular localization of R66A 
mutants in the context of both EGFP-8E7 and EGFP-8cE7 
 
n=5 # Nuclear # Pancellular # Cytoplasmic 
8E7 636 112 0 
8E7 R66A 658 111 0 
8cE7 668 54 0 
8cE7 R66A 608 54 0 
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FIG. 17. Mutations of hydrophobic residues but not arginine 66 within the 
zinc-binding domain disrupt the nuclear import of GST-8E7. Digitonin-
permeabilized HeLa cells were incubated with either GST-8E7 (panels A, B, C 
and D), GST-8E7LRLFV/AAAAA (panels E, F, G and H), GST-8E7R66A (panels I, J, K 
and L) or GST (panels M, N, O and P) in the presence of only transport buffer 
(panels A, E, I and M) or HeLa cytosol (panels C, G, K and O). Detection of the 
localization of the GST fusion proteins was performed with an anti-GST antibody. 
Panels A, C, E, G, I, K, M and O show the protein localization and panels B, D, F, 
H, J, L, N and P show the DAPI staining of the nuclei.  	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FIG. 18. 8E7 interacts with the FG repeats of Nup62. 24 hours post 
transfection with either EGFP-8E7 or EGFP, HeLa cell lysates were prepared 
and incubated with either GST-Nup62N, GST-Nup62C or GST which were 
immobilized on glutathione-Sepharose beads. Cell lysates and the eluted bound 
proteins were analyzed by immunoblotting with an anti-GFP antibody (EGFP-
8E7, lanes 1, 4, 7 and 10; EGFP, lanes 2, 5, 8 and 11; as a positive control, 
Kapβ2, 3, 6, 9 and 12).  	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FIG. 19.  8cE7 interacts with the FG repeats of Nup62. 24 hours post 
transfection with either EGFP-8cE7 or EGFP, HeLa cell lysates were prepared 
and incubated with either GST-Nup62N, GST-Nup62C or GST which were 
immobilized on glutathione-Sepharose beads. Cell lysates and the eluted bound 
proteins were analyzed by immunoblotting with GFP antibody (EGFP-8cE7, lanes 
1, 4, 7 and 10; EGFP, lanes 2, 5, 8 and 11; as a positive control, Kapβ2, 3, 6, 9 
and 12). 	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FIG. 20. HPV8 E7 interacts via its zinc-binding domain with the FG domain 
of Nup62 and mutations of hydrophobic residues disrupt its interaction. 24 
hours post transfection with either EGFP-8E7, EGFP-8E7LRLFV/AAAAA, EGFP-
8E7R66A, EGFP-8cE7, EGFP-8cE7LRLFV/AAAAA , EGFP-8cE7R66A or EGFP, HeLa 
cell lysates were prepared and incubated with either GST-Nup62N or GST which 
were immobilized on glutathione-Sepharose beads. Cell lysates and the bound 
proteins were eluted and analyzed by immunoblotting with an anti-GFP antibody 
(EGFP-8E7, lanes 1, 9, 17; EGFP-8E7LRLFV/AAAAA, lanes 2, 10, 18; EGFP-8E7R66A, 
lanes 3, 11, 19; EGFP-8cE7, lanes 4, 12, 20; EGFP-8cE7LRLFV/AAAAA, lanes 5, 13, 
21; EGFP-8cE7R66A , lanes 5, 14, 12; EGFP, lanes 7, 15, 23; as a positive 
control, Kapβ2, lanes 8, 16, 24). 	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FIG. 21. HPV8 E7 binds to Nup153 and mutations of hydrophobic residues 
within its zinc-binding domain inhibit this interaction. 24 hours post 
transfection with either EGFP-8E7, EGFP-8E7LRLFV/AAAAA, EGFP-8E7R66A, EGFP-
8cE7, EGFP-8cE7 LRLFV/AAAAA, EGFP-8cE7R66A or EGFP, HeLa cell lysates were 
prepared and incubated with either GST-Nup153 or GST which were immobilized 
on glutathione-Sepharose beads. Cell lysates and the bound proteins were 
eluted and analyzed by immunoblotting with a GFP antibody (EGFP-8E7, lanes 
1, 9, 17; EGFP-8E7LRLFV/AAAAA, lanes 2, 10, 18; EGFP-8E7R66A, lanes 3, 11, 19; 
EGFP-8cE7, lanes 4, 12, 20; EGFP-8cE7LRLFV/AAAAA, lanes 5, 13, 21; EGFP-
8cE7R66A, lanes 5, 14, 12; EGFP, lanes 7, 15, 23; as a positive control, Kapβ2, 
lanes 8, 16, 24). 	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FIG. 22. HPV16 E7 binds to Nup153 and mutations of hydrophobic residues 
within its zinc-binding domain inhibit this interaction. 24 hours post 
transfection with either EGFP-16E7, EGFP-16E7LRLCV/AAAAA, EGFP-16E7R66A, 
EGFP-16cE7, EGFP-16cE7LRLCV/AAAAA, EGFP-16cE7R66A or EGFP, HeLa cell 
lysates were prepared and incubated with either GST-Nup153 or GST which 
were immobilized on glutathione-Sepharose beads. Cell lysates and the bound 
proteins were eluted and analyzed by immunoblotting with a GFP antibody 
(EGFP-16E7, lanes 1, 9, 17; EGFP-16E7LRLCV/AAAAA, lanes 2, 10, 18; EGFP-
16E7R66A, lanes 3, 11, 19; EGFP-16cE7, lanes 4, 12, 20; EGFP-16cE7LRLCV/AAAAA, 
lanes 5, 13, 21; EGFP-16cE7R66A , lanes 5, 14, 12; EGFP, lanes 7, 15, 23; as a 
positive control, Kapβ2, lanes 8, 16, 24). 	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FIG. 23. HPV11 E7 binds to Nup153 and mutations of hydrophobic residues 
within its zinc-binding domain inhibit this interaction. 24 hours post 
transfection with either EGFP-11E7, EGFP-11E7VRLVV/AAAAA, EGFP-11E7R66A, 
EGFP-11cE7, EGFP-11cE7VRLVV/AAAAA , EGFP-11cE7R66A or EGFP, HeLa cell 
lysates were prepared and incubated with either GST-Nup153 or GST which 
were immobilized on glutathione-Sepharose beads. Cell lysates and the bound 
proteins were eluted and analyzed by immunoblotting with a GFP antibody 
(EGFP-11E7, lanes 1, 9, 17; EGFP-11E7VRLVV/AAAAA, lanes 2, 10, 18; EGFP-
11E7R66A, lanes 3, 11, 19; EGFP-11cE7, lanes 4, 12, 20; EGFP-11cE7VRLVV/AAAAA, 
lanes 5, 13, 21; EGFP-11cE7R66A, lanes 5, 14, 12; EGFP, lanes 7, 15, 23; as a 
positive control, Kapβ2, lanes 8, 16, 24). 	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FIG. 24. Excess of Kapβ2 prevents nuclear import of GST-8E7. Digitonin-
permeabilized HeLa cells were incubated with either GST-8E7 (panels A, B, C 
and D), M9-GST (panels E, F, G and H) or GST (panels I, J, K and L) in the 
presence of only HeLa cytosol (panels A, E and I) or HeLa cytosol plus Kapβ2 in 
excess  (panels C, G and K). Detection of the localization of the GST fusion 
proteins was performed with an anti-GST antibody. Panels A, C, E, G, I and K 
show the protein localization and panels B, D, F, H, J and L show the DAPI 
staining of the nuclei.  
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FIG. 25. An antibody to Nup62 FG repeats domain inhibits the nuclear 
import of GST-8E7. Digitonin-permeabilized HeLa cells were incubated with 
GST-8E7 (panels A, B, C, E, F and G) in the presence of transport buffer (panel 
A), only HeLa cytosol (B) or HeLa cytosol plus anti-Nup62 antibody  (C), or with 
GST in the presence of HeLa cytosol (panel D). Detection of the localization of 
the GST fusion proteins was performed with an anti-GST antibody. Panels A, B, 
C and D show the protein localization and panels E, F, G and H show the DAPI 
staining of the nuclei.  	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FIG. 26. EGFP-5E7 and EGFP-5cE7 are predominantly nuclear in HeLa 
cells. HeLa cells expressing either EGFP-5E7 (panels A and B), EGFP-5nE7 
(panels C and D) or EGFP-5cE7 (panels E and F) were fixed 24 hours after 
transfection and examined by confocal microscopy. EGFP fluorescence is shown 
in the top row (panels A, C and E), while DAPI staining of the nuclei is shown in 
the bottom row (panels B, D and F).  	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FIG. 27. Quantitative analysis of the localization of EGFP-5E7 and its 
subdomains. Cells transfected with either EGFP-5E7, EGFP-5nE7 or EGFP-
5cE7 were phenotyped as having either mostly nuclear (blue bars) or pancellular 
(red bars) and the quantitative analysis of 5 experiments is represented 
graphically.  	  	  	  	  	  	  	  
Table 6: Quantitative analysis of the intracellular localization of EGFP-5E7 
and its subdomains 
 
n=5 # Nuclear # Pancellular # Cytoplasmic 
5E7 824 261 0 
5nE7 120 899 0 
5cE7 914 195 0 
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FIG. 28. EGFP-5E7 and its subdomains are well expressed in HeLa cells. 
HeLa cells expressing either EGFP- 5E7 (lane1), EGFP-5nE7 (lane 2) or EGFP-
5cE7 (lane 3) were analyzed by immunoblotting with an anti-GFP antibody 24 
hours post transfection.  
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FIG. 29. GST-5E7 and GST-5cE7 are imported into the nuclei of digitonin- 
permeabilized HeLa cells. Digitonin-permeabilized HeLa cells were incubated 
with either GST-5E7 (panels A, B, C and D), GST-5nE7 (panels E, F, G and H), 
GST-5cE7 (panels I, J, K and L), M9-GST (panels M, N, O and P) or GST (panels 
Q, R, S and T) in the presence of only transport buffer (panels A, E, I, M and Q) 
or HeLa cytosol (panels C, G, K, O and S). Detection of the localization of the 
GST fusion proteins was performed with an anti-GST antibody. Panels A, C, E, 
G, I, K, M, O, Q and S show the protein localization and panels B, D, F, H, J, L, 
N, P, R and T show the DAPI staining of the nuclei.  	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FIG. 30. HPV5 E7 interacts via its zinc-binding domain with the FG domain 
of Nup62. 24 hours post transfection with either EGFP-5E7, EGFP-5cE7 or 
EGFP, HeLa cell lysates were prepared and incubated with either GST-Nup62N, 
GST-Nup62C or GST which were immobilized on glutathione-Sepharose beads. 
Cell lysates and the bound proteins were eluted and analyzed by immunoblotting 
with an anti-GFP antibody (EGFP-5E7, lanes 1, 5, 9, 13; EGFP-5cE7, lanes 2, 6, 
10, 14; EGFP, lanes 3, 7, 11, 15; as a positive control, Kapβ2, lanes 4, 8, 12, 16). 	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FIG. 31. HPV5 E7 interacts via its zinc-binding domain with Nup153. 24 
hours post transfection with either EGFP-5E7, EGFP-5cE7 or EGFP, HeLa cell 
lysates were prepared and incubated with either GST-Nup153 or GST which 
were immobilized on glutathione-Sepharose beads. Cell lysates and the bound 
proteins were eluted and analyzed by immunoblotting with an anti-GFP antibody 
(EGFP-5E7, lanes 1, 4, 7; EGFP-5cE7, lanes 2, 5, 8; EGFP, lanes 3, 6, 9; as a 
positive control, Kapβ2, lanes 10, 11, 12). 	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FIG. 32. Quantitative analysis of the intracellular localization of EGFP-8E7 
and its subdomains in the presence of Ratjadone A, a specific inhibitor of 
CRM1 nuclear export receptor. 20 hours post-transfection with either EGFP-
8E7, EGFP-8cE7, EGFP-8nE7 or EGFP-16E7NesRev, HeLa cells were treated with 
either fresh DMEM or 10ng/mL Ratjadone A for 4 hours.  After fixation, cells were 
phenotyped as having either mostly nuclear (blue bars), pancellular (red bars) or 
mostly cytoplasmic (green bars) and the quantitative analysis of 5 experiments is 
represented graphically.  	  	  	  
Table 7: Quantitative analysis of the effect of RJA on the intracellular 
localization of EGFP-8E7 and its subdomains 
 
n=5 # Nuclear # Pancellular # Cytoplasmic 
8E7 662 133 0 
8E7 + RJA 665 76 0 
8cE7  628 67 0 
8cE7 + RJA 590 41 0 
8nE7 37 767 0 
8nE7 + RJA 40 731 0 
16E7 NesRev 0 111 569 
16E7 NesRev + RJA 505 13 0 
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FIG. 33. Pancellular localization of EGFP-8cE7 cysteine mutants is rescued 
in the presence of Ratjadone A, a specific inhibitor of CRM1 nuclear export 
receptor. 20 hours post-transfection with either EGFP-8cE7 (panels A, B, C and 
D), EGFP-8cE7CC60AA (panels E, F, G and H) or EGFP-8cE7C91A (panels I, J, K 
and L), HeLa cells were treated with either fresh DMEM (panels A, B, E, F, I and 
J) or 10ng/mL Ratjadone A (panels C, D, G, H, K and L) for 4 hours.  After 
fixation, cells were examined by confocal microscopy. Panels A, C, E, G, I and K 
represent the EGFP fluorescence and panels B, D, F, H, J and L represent the 
DAPI staining of the nuclei.  
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FIG. 34. Quantitative analysis of the intracellular localization of EGFP-8cE7 
and its cysteine mutants in the presence of Ratjadone A, a specific 
inhibitor of CRM1 nuclear export receptor. 20 hours post-transfection with 
either EGFP-8cE7, EGFP-8cE7CC60AA, EGFP-8cE7C91A or EGFP-16E7NesRev, 
HeLa cells were treated with either fresh DMEM or 10ng/mL Ratjadone A for 4 
hours.  After fixation, cells were phenotyped as having either mostly nuclear (blue 
bars), pancellular (red bars) or mostly cytoplasmic (green bars) and the 
quantitative analysis of 5 experiments is represented graphically.  
 
 
 
 
 
Table 8: Quantitative analysis of the effect of RJA on the intracellular 
localization of EGFP-8cE7 and its cysteine mutants 
 
n=5 # Nuclear # Pancellular # Cytoplasmic 
8cE7 649 89 0 
8cE7 + RJA 562 46 0 
8cE7 CC60AA 71 619 0 
8cE7 CC60AA + RJA 614 70 0 
8cE7 C91A 98 744 0 
8cE7 C91A + RJA 633 78 0 
16E7 NesRev 0 169 595 
16E7 NesRev + RJA 504 18 0 
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FIG. 35. Quantitative analysis of the intracellular localization of EGFP-8E7 
and its cysteine mutants in the presence of Ratjadone A, a specific 
inhibitor of CRM1 nuclear export receptor. 20 hours post-transfection with 
either EGFP-8E7, EGFP-8E7CC60AA, EGFP-8E7C91A or EGFP-16E7NesRev, HeLa 
cells were treated with either fresh DMEM or 10ng/mL Ratjadone A for 4 hours.  
After fixation, cells were phenotyped as having either mostly nuclear (blue bars), 
pancellular (red bars) or mostly cytoplasmic (green bars) and the quantitative 
analysis of 5 experiments is represented graphically.  
 
 
 
Table 9: Quantitative analysis of the effect of RJA on the intracellular 
localization of EGFP-8E7 and its cysteine mutants 
 
n=5 # Nuclear # Pancellular # Cytoplasmic 
8E7 662 133 0 
8E7 + RJA 665 76 0 
8E7 CC60AA 645 219 0 
8E7 CC60AA + RJA 675 73 0 
8E7 C91A 639 200 0 
8E7 C91A + RJA 671 55 0 
16E7 NesRev 0 111 569 
16E7 NesRev + RJA 505 13 0 
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FIG. 36. HPV 8 and 5 E7 interact with CRM1 nuclear import receptor.  24 
hours post transfection with either EGFP-8E7, EGFP-5E7, EGFP-16E7NesRev or 
EGFP, HeLa cell lysates were prepared and incubated with either GST-CRM1 or 
GST which were immobilized on glutathione-Sepharose beads. Cell lysates and 
the bound proteins were eluted and analyzed by immunoblotting with an anti-
GFP antibody (EGFP-8E7, lanes 1, 5, 9; EGFP-5E7, lanes 2, 6, 10; EGFP-
16E7NesRev, lanes 3, 7, 11; EGFP, lanes 4, 8, 12). 	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FIG. 37. Mutations in potential NES change the localization of the EGFP-
8cE7C91A mutant. HeLa cells expressing either EGFP-8cE7 (panels A and E), 
EGFP-8cE7C91A (panels B and F), EGFP-8cE7C91A/F79 (panels C and G) or EGFP-
8cE7C91A/LLF82AAA (panels D and H) were fixed 24 hours after transfection and 
examined by confocal microscopy. EGFP fluorescence is shown in the top row 
(panels A, B, C and D), while DAPI staining of the nuclei is shown in the bottom 
row (panels E, F, G and H).  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  	   123	  
	  
	  
FIG. 38. Quantitative analysis of the effect of NES mutations on the 
localization of EGFP-8cE7C91A. Cells transfected with either EGFP-8cE7, 
EGFP-8cE7C91A, EGFP-8cE7C91A/F79A or EGFP-8cE7C91A/LLF82AAA were 
phenotyped as having either mostly nuclear (blue bars), pancellular (red bars) or 
mostly cytoplasmic (green bars) and the quantitative analysis of 5 experiments is 
represented graphically.  
	  
	  
	  
	  
	  
 
Table 10: Quantitative analysis of the effect of NES mutations on the 
intracellular localization of EGFP-8cE7 C91A	  
	  
 
n=4 # Nuclear # Pancellular # Cytoplasmic 
8cE7 515 53 0 
8cE7 C91A 106 452 59 
8cE7 C91A/F79A 509                          78 0 
8cE7 C91A/LLF82AAA 502 69 0 
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FIG. 39. Mutations in possible nuclear export signal in the context of EGFP-
8cE7C91A disrupt the interaction between 8E7 and CRM1. 24 hours post 
transfection with either EGFP-8cE7, EGFP-8cE7C91A, EGFP-8cE7C91A/F79, EGFP-
8cE7C91A/LLF82AAA or EGFP, HeLa cell lysates were prepared and incubated with 
either GST-CRM1 or GST which were immobilized on glutathione-Sepharose 
beads. Cell lysates and the bound proteins were eluted and analyzed by 
immunoblotting with an anti-GFP antibody (EGFP-8cE7, lanes 1, 6, 11; EGFP-
8cE7C91A, lanes 2, 7, 12; EGFP-8cE7C91A/F79, lanes 3, 8, 13; EGFP-
8cE7C91A/LLF82AAA, lanes 4, 9, 14; EGFP, lanes 5, 10, 15). 
	  	  	  	  	  
